

Cite this: *RSC Adv.*, 2019, 9, 12944

A review on the biosynthesis of metal and metal salt nanoparticles by microbes

Geeta Gahlawat† and Anirban Roy Choudhury *

Metal nanoparticles have received great attention from researchers across the world because of a plethora of applications in agriculture and the biomedical field as antioxidants and antimicrobial compounds. Over the past few years, green nanotechnology has emerged as a significant approach for the synthesis and fabrication of metal nanoparticles. This green route employs various reducing and stabilizing agents from biological resources for the synthesis of nanoparticles. The present article aims to review the progress made in recent years on nanoparticle biosynthesis by microbes. These microbial resources include bacteria, fungi, yeast, algae and viruses. This review mainly focuses on the biosynthesis of the most commonly studied metal and metal salt nanoparticles such as silver, gold, platinum, palladium, copper, cadmium, titanium oxide, zinc oxide and cadmium sulphide. These nanoparticles can be used in pharmaceutical products as antimicrobial and anti-biofilm agents, targeted delivery of anticancer drugs, water electrolysis, waste water treatment, biosensors, biocatalysis, crop protection against pathogens, degradation of dyes *etc.* This review will discuss in detail various microbial modes of nanoparticles synthesis and the mechanism of their synthesis by various bioreducing agents such as enzymes, peptides, proteins, electron shuttle quinones and exopolysaccharides. A thorough understanding of the molecular mechanism of biosynthesis is the need of the hour to develop a technology for large scale production of bio-mediated nanoparticles. The present review also discusses the advantages of various microbial approaches in nanoparticles synthesis and lacuna involved in such processes. This review also highlights the recent milestones achieved on large scale production and future perspectives of nanoparticles.

Received 21st December 2018
Accepted 17th April 2019

DOI: 10.1039/c8ra10483b

rsc.li/rsc-advances

1. Introduction

In recent times, research interest in metal nanoparticles and their production has increased significantly because of their innovative applications in different industrial domains.^{1,2} Nanoparticles are particulate dispersions of solid particles with at least one dimension between 1 and 100 nm. Nanoparticles have opened various fronts for the design of new materials and evaluation of their properties by modulating particle size, morphology and distribution.³ Metal nanoparticles have been explored widely due to their unique characteristics like anti-microbial, anticancer and catalytic activity, and magnetic and optical properties. The most important property of metal nanoparticles is their large surface area to volume ratio which increases their interaction with other molecules.⁴ Because of these remarkable and fascinating characteristics, nanoparticles are gaining significant attention in a diverse range of applications such as biochemical sensors, electronic equipment,

catalysts, bio-assay, tumor-imaging, drug delivery and pharmaceutical treatment procedures.^{5,6}

Generally nanoparticles are produced and stabilized either by a “top down” or “bottom up” strategy.⁷ In the “bottom up” strategy, nanoparticles are synthesized *via* self-assembly of atoms into nuclei which further develop into nanoscale particles. This approach includes chemical and biological methods of production whereas in the “top down” strategy, bulk material is broken down into small particles by size reduction using various physical and chemical techniques.^{8,9} The physical methods include grinding, milling and thermal ablation *etc.* On the other hand, the chemical approach of nanoparticles synthesis includes electrochemistry, chemical reduction, and photochemical reduction techniques. The physical approaches require high amount of energy which makes these types of processes more capital intensive. Another drawback of physical methods is the lower production yield of nanoscale materials.⁸ Over the past years, the chemical processes have been most preferable approach for nanoparticles synthesis because of requirement of less energy during reduction step and formation of homogenous particles with high preciseness in size and shape.³ However, chemical methods are environmentally hazardous because of the use of various perilous chemicals

CSIR – Institute of Microbial Technology, Sector 39A, Chandigarh, India. E-mail: anirban@imtech.res.in; Fax: +91 172 2695215; Tel: +91 172 6665312

† Present Address: Department of Microbiology, Panjab University, Sector-25, Chandigarh, India.



(hydrazine or potassium bitartrate) which are responsible for carcinogenicity, genotoxicity, and cytotoxicity.^{9,10} The use of chemical methods for synthesis of nanoparticles for biomedical application have been restricted because of toxicity, instability and less biocompatibility.^{11,12} Therefore, developing an environment friendly approach that effectively modulates the size, morphology, stability and characteristics is presently the main focus of research area on nanoparticle synthesis.¹³

The bio-mediated synthesis using microbes has evolved as a promising substitute to traditional methods of nanoparticles synthesis.¹⁴ Microbial synthesis is an environment-friendly green approach that exploits biological creatures such as bacteria, actinomycetes, fungi, algae, viruses and yeast for nanoparticles production. Microbial route provides a nontoxic, inexpensive and reliable way for nanoparticles synthesis with diversity in size, shape, composition, and physicochemical properties. This “green” route of nanoparticle synthesis is an attractive practice that enables synthesis in aqueous environment with minimum costs and low energy requirement, and can be easily scaled up to higher level.¹⁵ Another important property of these microbiological agents is their capability to serve as templates for the synthesis and organisation of nanoparticle into well-defined structures. Although several reviews have been published in past on nanoparticles biosynthesis, the present article aims to review the recent developments and progress made in nanoparticles synthesis in recent five to six years. This review paper mainly emphasizes on the utilization of various microbial agents for the metal nanoparticles synthesis, and understanding the possible mechanisms involved in fabrication of metal nanoscale particles. The present review will discuss various advantages and applications of microbial approaches in nanoparticles synthesis and lacuna involved in such processes. Finally, recent milestones achieved in large scale production and concluding remarks on future perspectives have been summarized.

2. Microbial synthesis of metal nanoparticles

In past few years, biosynthesis of nanoparticles using microbial agents such as bacteria, actinomycetes, fungi, yeast, viruses and marine algae has received tremendous attention in the area of green nanotechnology.¹⁴ Microorganisms serve as potential nanofactories for ecofriendly and inexpensive synthesis of different metallic nanoparticles like silver, gold, palladium and copper, and metal oxides such as zinc oxide, titanium oxide *etc.* These nanoscale structures could exist in different shapes and forms such as nanotubes, nanoconjugates, nanorods and nanowires *etc.* (Fig. 1).³ These different morphological forms have shown remarkable properties for use in biomedical applications as anticancer and antimicrobial compounds.

2.1 Bacteria and actinomycetes

Bacteria possess unique ability to reduce metallic ions into nanoparticles and are one of the most suitable candidates for nanoparticles synthesis because of their ease of handling and

high growth rates. As opposed to other microbes, bacteria can be easily moulded and manipulated genetically for the biomineralization of metal ions.¹⁶ Bacteria are continuously exposed to harsh and toxic environment conditions resulting from high concentrations of heavy metal ions in their surroundings. However, they have evolved various natural defence mechanisms such as intracellular sequestration, efflux pumps, change in metal ion concentration and extracellular precipitation, to cope up with these stress conditions.¹⁷ These defence mechanisms can be efficiently utilized by the bacteria for the synthesis of nanoparticles for different kind of applications. Table 1 shows the list of different bacterial strains adopted for the fabrication of nanoparticles and their respective applications.

Bacteria are generally known to synthesize metal nanoparticles either by extracellular or intracellular mechanisms. Beveridge and Murray first time reported the deposition of gold nanoparticles (AuNP) extracellularly on *Bacillus subtilis* cell wall when gold chloride solution was used to suspend unfixed wall.¹⁸ In another report, a silver-resistant strain of *Pseudomonas stutzeri* AG259 accumulated silver nanoparticles (AgNP) intracellularly within size range of few nm to 200 nm using NADH-dependent reductase enzyme that supplies electrons and itself oxidises to NAD⁺.¹⁹ The transfer of electrons from NADH results in the bioreduction of silver ions into silver nanoparticles. In 2012, Srivastava *et al.* concluded that *Pseudomonas aeruginosa* has the capability to synthesize variety of nanoparticles intracellularly such as Pd, Ag, Rh, Ni, Fe, Co, Pt, and Li nanoparticles.²⁰ This work did not include any external stabilizing agent and electron donors and was free from the step of modifying pH during the biomineralization step of different metal ions. In recent reports, different bacterial strains such as *Escherichia coli*, *Bacillus subtilis*, *Bacillus megaterium*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Bacillus cereus*, *Alteromonas* and *Ochrobactrum* *etc.* have been extensively used for nanoparticles synthesis (Table 1).

Das *et al.* revealed the extracellular synthesis of silver nanoparticle at ambient temperature in 24 h using *Bacillus cereus* isolated from heavy metal contaminated soil.²¹ Synthesized AgNPs showed surface plasmon resonance properties which could be useful in various application. Kulkarni *et al.* elucidated the extracellular biosynthesis of AgNPs using radiation resistant *Deinococcus radiodurans* via reduction of silver chloride solution.²² The AgNPs showed broad-spectrum antibacterial and anti-biofilm activity against both Gram negative and Gram positive bacteria. The AgNPs also showed excellent anticancerous activity against human breast cancer cell lines. The cell viability and cytotoxicity assay demonstrated that AgNPs can inhibit the proliferation of cancer cell lines. *D. radiodurans* can withstand high radiation and desiccation condition which suggest that it can be used for on-field application for bioremediation. Researchers are now shifting towards the synthesis and development of different type of nanoparticles such as palladium, platinum and tellurium *etc.* specifically targeting them for various end uses. For example, Ahmed *et al.* reported synthesis of ultra small palladium and platinum nanoparticles by *Shewanella loihica* PV-4 within the





Fig. 1 A mechanistic scheme with graphical representation about the synthesis of metal nanoparticles from microbes [this figure has been adapted from ref. 163 with permission from Royal Society of Chemistry].

size range of 2–7 nm.²³ In this report, electrochemically active biofilms of *S. loihica* were employed for the successful synthesis of ultra small nanoparticles. The synthesized palladium and platinum nanoparticles have shown excellent catalytic performance in decomposition of methyl orange dye. Zonaro *et al.* described the synthesis of tellurium nanoparticles using *Ochrobactrum* sp. and concluded that this strain can serve as a potential nanofactory for the conversion of toxic tellurite oxyanions into useful nanoparticles.²⁴ In recent study, Srinath *et al.* described the synthesis of AuNPs using *Bacillus subtilis* isolated from Hatti Gold Mine, India.²⁵ The microorganisms isolated from gold mine have high resistance to gold ions toxicity and can synthesize AuNPs efficiently. The AuNPs served as biocatalyst in degradation of methylene blue and can be used to degrade other toxic dyes in the environment. Saravanan *et al.* used *Bacillus brevis* for the synthesis of spherical silver nanoparticles within the size range of 41–62 nm.²⁶ In this work, AgNPs showed remarkable antibacterial activity against multi-drug resistant strains of *Salmonella typhi* and *Staphylococcus aureus*.

The reduction of metallic ions into nanoparticles is considered to be dependent on a variety of factors. The first important factor is organic functional molecules present on the cell wall that induce biomineralization, and another essential factor is

suitable environmental conditions such as pH, composition of medium, metallic salt concentration and temperature.¹⁹ Nanoparticle size, morphology and composition can be significantly affected by these environment parameters.²⁷ Therefore, it is essential to optimize these factors during biosynthesis step to increase the overall efficiency of particles. For example, Ramanathan *et al.* synthesized silver nanoparticles (AgNPs) using *Morganella psychrotolerans* and optimized growth kinetics parameters to study their effect on AgNPs morphology.²⁸ At optimum growth temperature of 20 °C, spherical AgNPs were produced with average diameter of 2–5 nm, while a mixture of triangular and hexagonal nanoplates along with spherical nanoparticles were obtained at 25 °C. As temperature was decreased from 20 °C to 15 °C, again a mixture of nanoplates and spherical particles were obtained. Further reduction in bacterial physiological activity and growth by decreasing its optimum growth temperature to 4 °C resulted in a significant increase in the number of nanoplates, with only small number of spherical nanoparticles. Moreover, the spherical nanoparticles formed at 4 °C were larger in size around 70–100 nm. In another study, Yumei *et al.* studied the AgNP synthesis using *Arthrobacter* sp. and demonstrated that synthesis of nanoparticle can be modulated by metal ion concentration, temperature and pH.²⁹ Low concentrations of silver nitrate (1



Table 1 A representative list of bacteria and actinomycetes used for the synthesis of nanoparticles and their applications

Bacteria	Source of isolation	Metal nanoparticles	Characterization			Reference
			Size (nm)	Shape	Applications	
<i>Bacillus cereus</i>	Leaf of <i>Garcinia xanthochymus</i>	Silver	20–40	Spherical	Antibacterial activity	34
<i>Stenotrophomonas</i> GSG2	Coral sample collected from Bay of Bengal	Silver and gold	Gold – 10 to 50; silver – 40 to 60	Circular, triangular, hexagonal	nd	30
<i>Alteromonas macleodii</i>	Sediment sample from Kochi back water, India	Silver	70	Spherical	nd	32
<i>Alcaligenes faecalis</i>	Coral from Palk Bay located near Mandapam, Gulf of Mannar	Silver	30–50	Spherical	Antimicrobial and anti-biofilm activity	35
<i>Bacillus</i> sp. CS11	Soil samples from Cochin, India	Silver	42–92	Spherical	nd	21
<i>Kocuria flava</i>	Kanyakumari coast of India	Copper	5–30	Spherical	nd	31
<i>Deinococcus radiodurans</i>	American Type Culture Collection, Manassas, USA	Silver	4–50	Spherical	Antibacterial activity, anti-biofouling agent and anticancer activity	22
<i>Ochrobactrum rhizosphaerae</i>	Marine water	Silver	10	Spherical	Antibacterial activity	4
<i>Pseudomonas aeruginosa</i> JP-11	Marine water	Cadmium sulphide	20–40	Spherical	Removal of cadmium pollutant from aqueous solution	33
<i>Klebsiella pneumoniae</i> , <i>Escherichia coli</i> , <i>Pseudomonas jessinii</i>	Isolated from tiger nut, carrot juice and feces	Silver	50–100	Cubic and star/flower like shapes	nd	36
<i>Pseudomonas aeruginosa</i>	Mangrove Water Sample Mandovi Estuary	Silver	35–60	Spherical and triangular	Antibacterial activity	37
<i>Shewanella loihica</i> PV-4	DSMZ, Germany	Palladium and platinum	2–7	Spherical	Degradation of methyl orange dye	23
<i>Morganella psychrotolerans</i>	—	Silver	2–5	Spherical	—	28
<i>Ochrobactrum</i> sp. MPV1	Roasted Arsenopyrites, Tuscany, Italy	Tellurium	nd	Roughly spherical and rods	Reduction of toxic compounds	24
<i>Bacillus subtilis</i>	Hutti gold mine, India	Gold	20–25	Spherical	Degradation of methylene blue	25
<i>Bacillus brevis</i> NCIM 2533	National Collection of Industrial Microorganism (NCL), Pune, India	Silver	41–68	Spherical	Antibacterial activity against multi-drug resistant bacteria	26
Actinomycetes						
<i>Rhodococcus</i> NCIM 2891	nd	Silver	10	Spherical	nd	39
<i>Rhodococcus</i> sp. NCIM 2891	National Chemical Laboratory, India	Silver	10–15	Spherical	Antimicrobial activity, catalytic reduction of 4-nitrophenol	45
<i>Streptomyces</i> sp. LK3	Marine soil sample, Nicobar Island	Silver	5	Spherical	Acaricidal activity	40
<i>Streptacidiphilus durhamensis</i>	Acidic forest soil	Silver	8–48	Spherical	Antibacterial and anticancer activity	41
<i>Streptomyces rochei</i> MHM13	Sediment samples along Suez Gulf, Red Sea, Egypt	Silver	22–85	Spherical	Antimicrobial activity and synergistic effect with antibiotics	42
<i>Streptomyces griseoruber</i>	Soil Sample, Mercara region	Gold	5–50	Spherical, hexagonal and triangular	Degradation of methylene blue	43
<i>Streptomyces parvulus</i>	DPUA Culture Collection, Brazil	Silver	1–40	nd	Antimicrobial activity	46
<i>Streptomyces capillispiralis</i> Ca-1	Medicinal plant <i>Convolvulus arvensis</i>	Copper	3.6–59	Spherical	Antimicrobial activity	44
<i>Streptomyces xinghaiensis</i> OF1	Sediment sample of Lonar Crater, Maharashtra, India	Silver	5–20	Spherical	Antimicrobial activity and synergistic effect with antibiotics	47



mM) synthesized face-centred-cubic AgNPs with size in between 9 to 72 nm at 70 °C and pH 7 to 8. On increasing the silver nitrate concentration to 3 mM, aggregation of AgNPs was observed at 70 °C. However, no AgNPs synthesis was reported below 5 and above 8 pH, and synthesis was found to be facilitated within the range of 7 to 8 pH. Upon increasing the incubation temperature from 70 °C to 90 °C, there was decrease in synthesis time from 10 min to 2 min. This study concluded that medium pH and metal ion concentration have direct influence on nanoparticle synthesis.

Till few years ago most of the researchers were mainly focused on terrestrial bacteria only. Recently, marine microbial cultures have also been explored extensively as nanofactories for nanoparticles synthesis. Malhotra *et al.* explored the potential of novel marine bacterium, *Stenotrophomonas* for the biosynthesis of AuNPs and AgNPs.³⁰ The research work investigated that low molecular weight secretory proteins present in supernatant were responsible for AuNPs and AgNPs biosynthesis. Similarly, Kaur *et al.* identified a new marine strain, *Kocuria flava* capable of synthesizing copper nanoparticle with particle size within the range of 5 to 30 nm.³¹ Various literature reports have explored nanoparticles synthesis using bacterial extracellular polymeric substances (EPS) which act as effective bio-reductant and capping agent.^{4,32,33} For example, Mehta *et al.* demonstrated application of EPS, secreted by an osmotolerant marine isolate *Alteromonas macleodii*, for the production of silver nanoparticle having narrow size distribution.³² Table 1 gives an overview of results of various other recent reports on nanoparticles biosynthesis by different bacteria.^{21–37} The table also highlights the application of these nanoparticles in bioremediation and biomedical field.

Actinomycetes have been generally used for the synthesis of extracellular enzymes and secondary metabolites.³⁸ They have also been adopted for the biosynthesis of nanoparticles as they have unsurpassed capacity for the production of various bioactive compounds and contain high protein content. Actinomycetes synthesize nanoparticles *via* both intracellular and extracellular pathway, but extracellular reduction is the most common pathway and has more commercial applications in different fields. In 2012, Otari *et al.* explained the green biosynthesis of silver nanoparticles using actinobacteria *Rhodococcus* NCIM 2891.³⁹ The TEM graph analysis of AgNPs revealed spherical shape with an average diameter of 10 nm. Intracellular biomineralization of silver ions was thought to be the result of enzymes present on the cell wall, resulting in production of silver nuclei. Karthik *et al.* adopted the marine bacterium, *Streptomyces* sp. LK-3 for the reduction of silver ion into AgNPs.⁴⁰ Their study concluded that nanoparticles were synthesized extracellularly and NADH-dependent nitrate reductase was mainly responsible for the reduction of silver ion into stable AgNPs *via* an electron transfer reaction. The AgNPs exhibited strong acaricidal or antiparasitic activity against *Rhipicephalus microplus* and *Haemaphysalis bispinosa*. Recently, Buszewski *et al.* employed an acidophilic actinobacteria, *Streptacidiphilus durhamensis* for the synthesis of silver nanoparticles.⁴¹ Their work displayed formation of stable spherical AgNPs within size range of 8 to 48 nm which showed the

antibacterial activity against *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Proteus mirabilis*. Generally, biosynthesized nanoparticles exhibit higher antimicrobial activity in comparison to traditionally synthesized nanoparticles due to the action of various bioactive molecules involved in capping and stabilization of the nanoparticles. Later on, Abd-Elnaby *et al.* screened 41 actinomycetes isolates from Suez Gulf, Red Sea and found that only two strains were capable of synthesizing AgNPs.⁴² Moreover, AgNPs exhibited a strong antibacterial activity against various pathogenic bacteria such as *Pseudomonas aeruginosa*, *Escherichia coli*, *Bacillus subtilis*, *Staphylococcus aureus*, *Salmonella typhimurium*, *Vibrio damsela*, *Vibrio fluvialis*, *Bacillus cereus*. It can be concluded that AgNPs remains the most widely studied nanoparticles by actinomycetes. However, there are recent reports which have described synthesis of copper and gold nanoparticles using *Streptomyces griseoruber* and *Streptomyces capillispiralis* Ca-1 respectively.^{43,44} Among actinomycetes, species of *Streptomyces* are most widely used in pharmaceutical and enzymatic applications because, out of more than 10 000 known antibiotics, 55% are produced by them. Table 1 summarizes list of various recent reports on nanoparticles synthesis by actinomycetes and their applications.^{39–47}

2.2 Fungi and yeast

Fungal biosynthesis of nanoparticles is another simple and straightforward approach which has been explored extensively for fabrication of nanoparticle. In comparison to bacteria, fungi have higher productivity in terms of nanoparticles generation and higher tolerances to metals especially in context of high cell wall binding capacity of metal ions with biomass.¹⁴ The downstream processing and biomass treatments are relatively easy in fungi as compared to bacteria and viruses. Moreover, fungi possess higher bioaccumulation ability towards metal ions resulting in an efficient and cost-effective production of nanoparticles. However, the process parameters have a significant effect on the biosynthesis of nanoparticles. An in-depth investigation of different process parameters was carried out by Bhargava *et al.* to study the effect of pH, salt concentration, and reaction time on the particle size and yield of fungi *Cladosporium oxysporum* to convert gold ion into nanoparticles.⁴⁸ The maximum yield of AuNPs was obtained with biomass to water ratio of 1 : 5 at 1 mM salt concentration and 7 pH. Moreover, the synthesized AuNPs exhibited excellent catalytic activity in the degradation of textile dye, rhodamine B within 7 min. Mishra *et al.* also described the extracellular formation of gold nanoparticles by culture filtrate of *Hypocrea lixii* and *Trichoderma viride*, and studied the effect of reaction temperature and incubation time on nanoparticles biosynthesis.⁴⁹ *T. viride* reported AuNPs biosynthesis within 10 min at 30 °C which further served as biocatalyst and strong antimicrobial agents. Metuku *et al.* collected a white rot fungus, *Schizophyllum radiatum* from Eturnagaram forest of Warangal, India and found it capable of producing well-dispersed stable silver nanoparticles.⁵⁰ Their research work investigated the potential of white rot fungus in the extracellular biomineralization of silver ion to nanoparticles of size 10 to 40 nm. These small size AgNPs demonstrated



strong antibacterial activity against various pathogenic Gram negative and Gram positive bacterial strains. Most of the studies reported till date have explained the involvement of extracellular component in the fabrication of nanomaterials. Main advantage of extracellular mediated nanoscale material synthesis is that it is devoid of impurities such as intracellular proteins, and treatment with detergents, ultrasound are not required.

Apart from this, understanding the mechanistic aspects of nanoparticles synthesis has also become indispensable for developing reliable applications. To overcome this knowledge gap, Rajput *et al.* explored various fungal strains of *Fusarium oxysporum* for silver nanoparticle synthesis and studied the effect of isolate selection, temperature and pH on nanoparticles morphology.⁵¹ Their study summarized that understanding the interactions between organic and interfacial layer will be helpful in developing novel uses, mainly in the area of biosensors. To further explore the bioinspired formation of nanoparticles, Kitching *et al.* extracted the cell surface proteins of *Rhizopus oryzae* for *in vitro* production of gold nanoparticles for biomedical and biocatalytic applications.⁵² In 2017, Suryavanshi *et al.* explored the synthesis of aluminium oxide nanoparticles using *Colletotrichum* sp., and nanoparticles were functionalized by essential oils extracted from the *Eucalyptus globulus* and *Citrus medica*.⁵³ The results concluded that nanofunctionalized oil can be used as antimicrobial agents against food-borne pathogens for the prevention of food spoilage. Recently, two filamentous fungi *Penicillium citreonigrum* and *Scopulariopsis brumptii*, and an edible mushroom, *Pleurotus ostreatus* have also been adopted for the synthesis of nanoparticles for anti-cancer and antimicrobial application, respectively.^{54,55} Table 2 depicts the list of various fungi that have been used for the biosynthesis of different metallic nanostructures for various applications.^{48–66}

Apart from fungi, some researchers have investigated the use of yeasts for the biogenic synthesis of the nanoparticles. Yeast possess the inherent capability to absorb and accumulate high concentrations of toxic metal ions from their surroundings.¹¹ Yeast cells adapt themselves under metal toxicity conditions using various detoxification mechanisms *viz.* bio-precipitation, chelation, and intracellular sequestration. This property of yeast cells has been exploited by various researchers. For example, in one study a marine strain of ascomycetous yeast *Yarrowia lipolytica* was employed for the biomimetic synthesis of silver nanoparticles in a cell associated manner.⁶⁷ The study concluded that possibly brown pigment (melanin) obtained from the yeast cells was responsible for biomineralization of metal ions. The pigment-derived silver nanoparticles displayed antibiofilm activity against *Salmonella paratyphi* pathogen. In another research work, Waghmare *et al.* reported the eco-friendly extracellular biosynthesis of AgNP using *Candida utilis* NCIM 3469.⁶⁸ Nanoparticles were circular in shape with size in-between 20 to 80 nm and showed antibacterial activity against pathogenic strains *i.e.* *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Escherichia coli*. In a recent study, Elahian *et al.* utilized a genetically modified yeast, *Pichia pastoris* for the biosynthesis of silver nanoparticles.⁶⁹ Engineered *Pichia pastoris*

strain overexpressed a metal-resistant gene, cytochrome b5 reductase enzyme obtained from *Mucor racemosus*, for the reduction of metal ion into nanoparticles. The cytochrome b5 reductase enzyme leads to synthesis of stable and well-dispersed metal nanoparticles within size range of 70–180 nm. In 2016, Eugenio *et al.* isolated a yeast strain, *Candida lusitanae* from gut of a termite and demonstrated production of silver nanoparticles with diameter in the range of 2–10 nm.⁷⁰ The silver nanoparticles showed antiproliferative activity against *S. aureus* and *Klebsiella pneumoniae*, and presented a promising alternative to commonly used antibiotics. Sriramulu and Sumathi (2018) employed *Saccharomyces cerevisiae* aqueous extract for the synthesis of hexagonal palladium nanoparticles (PdNPs) of size 32 nm.⁷¹ PdNPs showed photocatalytic degradation of textile azo dye (direct blue 71) to 98% within 60 min under UV light. All these literature reports suggested that the difference in nanoparticle size, shape and properties is because of the different mechanisms adopted by yeast cells to synthesize and stabilize the nanoparticles. Table 2 shows the list of various yeasts used for the synthesis of different metal nanoparticles.^{67–84}

2.3 Algae

Similarly to yeast, there are diverse literature reports on algae being used as a “nanofactory” for biosynthesis of metal nanoparticles (Table 3). Ferreira *et al.* employed the dried unicellular microalga, *Chlorella vulgaris* for the biosynthesis of silver nanoparticles within range of 9.8 ± 5.7 nm.⁸⁵ The spherical shaped nanoparticles were observed to be a promising green alternative for biomedical application as antimicrobial agents. In another study, Arsiya *et al.* evaluated the synthesis of palladium nanoparticles using *Chlorella vulgaris* aqueous extract within 10 min.⁸⁶ TEM results revealed that the nanoparticles were circular and mono-dispersed in nature having size of 5 to 20 nm. This study first time reported synthesis of palladium nanoparticles in a comparatively shorter time duration using *C. vulgaris*. The biosynthesis of palladium nanoparticles has also been reported using marine alga, *Sargassum bovinum* which is isolated from Persian Gulf area.⁸⁷ Dhas *et al.* explored the synthesis of silver chloride nanoparticles using the aqueous extract of marine alga, *Sargassum plagiophyllum*.⁸⁸ Recently, an economical green method has been reported for the synthesis of silver nanoparticles using a marine green alga, *Caulerpa racemosa*.⁸⁹ The synthesized nanoparticles exhibited remarkable catalytic activity towards the degradation of methylene blue. Ramakrishna *et al.* studied the synthesis of gold nanoparticles using aqueous extracts of brown algae, *Sargassum tenerrimum* and *Turbinaria conoides*.⁹⁰ The AuNPs displayed excellent biocatalytic activity in the degradation of aromatic nitro compounds and organic dyes. The metal nanoparticles of zinc oxide (ZnO) have also generated curiosity among researchers due to their unique physicochemical characteristics and wide applications in opto-electronics, sunscreens, biomedicine and food additives *etc.* Rajeshkumar (2018) adopted two marine brown seaweeds such as *Padina tetrastrum* and *Turbinaria conoides* algal formulation for the biosynthesis



Table 2 A representative list of fungi and yeast used to synthesize metal nanoparticles and their applications

Fungi	Source of isolation	Metal nanoparticle	Characterization		Applications	Reference
			Size (nm)	Morphology		
<i>Penicillium diversum</i>	Microbial Type Culture Collection, Chandigarh, India	Silver	10–50	Roughly spherical	Antimicrobial activity	56
<i>Aspergillus foetidus</i>	Kalyani Waste Water Centre, West Bengal India	Silver	20–40	Roughly spherical	Antifungal activity	57
<i>Fusarium oxysporum</i> sp. <i>cubense</i> JT1	Isolated from wilt infected banana plants	Gold	22	nd	Antimicrobial activity	58
<i>Trichoderma harzianum</i>	Procured from College of Life Sciences, Gwalior, India	Cadmium sulfide	3–8	Spherical	Photocatalytic activity	59
<i>Botrytis cinerea</i>	Isolated from rotten grapes collected from Region IV, Chile	Gold	1–100	Triangular, spherical, hexagonal, pyramidal, decahedral	nd	60
<i>Nigrospora oryzae</i>	nd	Gold	6–18	Cubic and spherical	Anthelmintic activity	61
<i>Schizophyllum radiatum</i> HE863742.1	Eturnagaram forest, Andhra Pradesh, India	Silver	10–40	Irregular shapes	Antimicrobial activity	50
<i>Trichoderma viride</i> and <i>Hypocrea lixii</i>	Microbial Type Culture Collection, Chandigarh, India	Gold	61	Triangles, rods, spheres, hexagons	Biocatalytic and antimicrobial activity	49
<i>Aspergillus terreus</i>	Microbial Type Culture Collection, Chandigarh, India	Zinc oxide	28–63	Spherical	Anticancer activity	62
<i>Curvularia lunata</i>	Leaves of <i>Catharanthus roseus</i>	Silver	10–50	Spherical	Synergistic antimicrobial activity	63
<i>Metarhizium anisopliae</i>	T-Stanes & Company Limited, Tamil Nadu, India	Silver	28–38	Rod-shaped	Mosquitocidal activity against <i>Anopheles culicifacies</i>	64
<i>Cladosporium oxysporum</i> AJP03	Soil from Sonshi mining region, Goa, India	Gold	72 ± 21	Spherical	Degradation of rhodamine B	48
<i>Fusarium oxysporum</i> 405	Obtained from American Research Service, Washington, USA	Silver	10–50	Spherical	Colloidal stability	51
<i>Rhizopus oryzae</i>	National Collection of Industrial Microorganism (NCIM), Pune, India	Gold	16–43	Spherical and Flower like	Hemcompatible activity	52
<i>Trichoderma harzianum</i>	nd	Silver	20–30	Spherical	Antifungal activity	65
<i>Colletotrichum</i> sp.	Amravati University, Amravati, India	Aluminium oxide	30–50	Spherical	Antimicrobial activity	53
<i>Fusarium oxysporum</i>	National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran	Silver	34–44	Spherical	Antibacterial activity	66
<i>Pleurotus ostreatus</i>	Biotechnology Center, Cairo University, Egypt	Gold	10–30	Spherical and prism shape	Anticancer and synergistic antimicrobial activity	54
<i>Penicillium citreonigrum</i>	East of Lake Burullus, Egypt	Silver	6–26	Spherical	Antibacterial activity	55
Yeast						
<i>Rhodospiridium diobovatum</i>	Isolated from Indian Ocean	Lead sulfide	2–5	Spherical	Lead accumulation	72
<i>Yarrowia lipolytica</i> NCYC789	National Collection of Yeast Cultures, Norwich, U.K.	Silver	15	-	Antibiofilm activity	67
<i>Candida utilis</i> NCIM 3469	National Collection of Industrial Microorganism (NCIM), Pune, Maharashtra, India	Silver	20–80	Spherical	Antibacterial activity	68
<i>Cryptococcus laurentii</i>	nd	Silver	35 ± 10	Roughly spherical	Antitumor activity	73



Table 2 (Contd.)

Fungi	Source of isolation	Metal nanoparticle	Characterization		Applications	Reference
			Size (nm)	Morphology		
<i>Saccharomyces cerevisiae</i>	Purchased from local market	Silver	2–20	Spherical	nd	74
<i>Magnusiomyces ingens</i> LH-F1	Sea mud of Harbor Industrial Zone, Dalian, China	Gold				75
<i>Pichia pastoris</i>	Recombinant strain overexpressing <i>Mucor racemosus</i> cytochrome b5 reductase	Silver	70–180	Spherical	nd	69
<i>Candida lusitanae</i>	Isolated from gut of <i>Cornitermes cumulans</i> termite	Silver and silver chloride	2–10	Cubical, cuboctahedral, icosahedral and spherical	Antiproliferative and microbicidal activity	70
<i>Cryptococcus laurentii</i> ; <i>Rhodotorula glutinis</i>	Isolated from apple peel	Silver	15–35	Spherical	Antifungal activity	76
<i>Saccharomyces cerevisiae</i>	AB Mauri (P) Ltd, Bangaluru, Karnataka, India	Gold nanoplates	—	Hexagonal and triangular nanoplates	Surface-plasmon enhanced applications	77
<i>Candida albicans</i> ATCC 10231	American Type Culture Collection, Manassas, USA	Silver	10–20	Spherical		78
<i>Pichia kudriavzevii</i>	Isolated from Sourdoughs and Tanzanian Togwa	Zinc oxide	10–61	Hexagonal wurtzite structure	Antioxidant and antibacterial property	79
<i>Rhodotorula mucilaginosa</i>	Copper Waste Pond at the Sossego Mine, Brazil	Silver	11	Spherical	Bioremediation of silver ions	80
<i>Phaffia rhodozyma</i>	American Type Culture Collection (ATCC), USA	Silver and gold	Silver: 5–9, gold: 4–7	Spherical and quasi-spherical	Antifungal activity	81
<i>Magnusiomyces ingens</i> LH-F1	Sea mud of Harbor Industrial Zone, Dalian, China	Gold	20.3–28.3	Spherical and pseudo-spherical	Catalyst for nitrophenols reduction	82
<i>Rhodotorula glutinis</i>	Soil Sample of Pici Campus, The Federal University of Ceará, Brazil	Silver	15.45 ± 7.94	Spherical	Antifungal activity, degradation of nitrophenol and methylene blue	83
<i>Saccharomyces cerevisiae</i>	Purchased from Pagariya Food Products (P) Ltd, Tamil Nadu, India	Palladium	32	Hexagonal	Degradation of textile dyes	71
<i>Candida glabrata</i>	Oropharyngeal Mucosa of HIV patients	Silver	2–15	Spherical	Antimicrobial activity	84

of ZnO nanoparticles and evaluated their antimicrobial potential against fish pathogens.⁹¹ In another recent work, San-aeimehr *et al.* synthesized ZnO nanoparticles using *Sargassum muticum* extract and established their antiangiogenic and anti-apoptotic potential against human liver cancer cell lines.⁹² All these literature reports indicates that researchers are now exploring marine organisms for the biogenic synthesis of nanoparticles because marine algae contain various biologically active compounds and secondary metabolites that allow them to act as “nanofactories”.⁹³ These marine algae have lots of applications in biomedicine as antioxidants, anticancer, anti-diabetic, cardioprotective, hepatoprotective and antiviral agents. Table 3 highlights the results of recent reports on algae-based biosynthesis of metal nanoparticles for different biological applications.^{85–108}

2.4 Viruses

An interesting property of viruses is their thick outer surface coating of capsid proteins which provide a highly suitable platform for interaction with metallic ions.¹⁰⁹ These protein cages can build monodispersed units that are highly robust and mouldable through genetic engineering. Viruses can be modified to serve as templates for material deposition or engineered to create three-dimensional vessels for targeted drugs delivery.¹¹⁰ Viruses can be employed for the synthesis of nano-conjugates and nanocomposites with metal nanoparticles which are important bioengineering materials in drug delivery and cancer therapy (Table 4). Mao *et al.* investigated the use of M13 bacteriophage for the nucleation and orientation process of semiconductor nanocrystals.¹¹¹ This group showed a genetically controllable biogenic synthesis route to a semiconductor



Table 3 A representative list of algae used for the synthesis of nanoparticles and their applications

Algae	Source of isolation	Metal nanoparticle	Characterization		Applications	Reference
			Size (nm)	Morphology		
<i>Porphyra vietnamensis</i>	nd	Silver	13	Spherical	Antibacterial activity	94
<i>Stoechospermum marginatum</i>	Tuticorin Coast, Tamil Nadu, India	Gold	19–94	Spherical, hexagonal and triangular	Antibacterial activity	95
<i>Tetraselmis kochinensis</i>	nd	Gold	05–35	Spherical and triangular	nd	96
<i>Chaetomorpha linum</i>	Kanyakumari Coast, India	Silver	03–44	Clusters	nd	97
<i>Sargassum plagiophyllum</i>	Rameshwaram Coast, Tamil Nadu, India	Silver	18–42	Spherical	Antibacterial potential	88
<i>Spirogyra varians</i>	Sweet water areas, Kerman, Iran	Silver	35	Quasi-sphere	Antibacterial activity	98
<i>Scenedesmus</i> sp.	CSIR – Institute of Minerals and Materials Technology, Bhubaneswar, India	Silver	15–20	Spherical crystalline	Antibacterial assay	99
<i>Chlorella vulgaris</i>	Algal Culture Collection, Chennai, India	Gold	02–10	Spherical self assembled cores	Anti-pathogenic activity	100
<i>Ecklonia cava</i>	Busan, South Korea	Gold	30	Spherical and triangular	Antimicrobial activity	101
<i>Caulerpa racemosa</i>	Gulf of Mannar, Southeast Coast, India	Silver	05–25	Spherical and triangular	Antibacterial assay	102
<i>Sargassum bovinum</i>	Persian Gulf area, South Western, Iran	Palladium	05–10	Octahedral	Hydrogen peroxide sensor	87
<i>Ulva lactuca</i>	Coastal areas of Rameshwaram, Tamilnadu, India	Silver	20–35	Cubical	Antiplasmodial activity	103
<i>Pithophora oedogonia</i>	Fresh Water Pond of Hoogly, West Bengal, India	Silver	25–44	Cubical and hexagonal	Antibacterial activity	104
<i>Caulerpa racemosa</i>	Mandapam Coastal Area, Tamil Nadu, India	Silver	25	Distorted spherical	Degradation of methylene blue	89
<i>Sargassum tenerrimum</i> and <i>Turbinaria conoides</i>	Mandapam Coast, Tamil Nadu, India	Gold	27–35	Spherical	Reduction of dyes – rhodamine B and sulforhodamine 101	90
<i>Chlorella vulgaris</i>	Culture Collection of Algae, University of Texas, Austin	Silver	03–15	Spherical	Antibacterial activity	85
<i>Cystoseira baccata</i>	Northwest Coast of Spain	Gold	8.4	Spherical	Anticancer activity	105
<i>Chlorella vulgaris</i>	Faculty of Natural Resources and Environment, University of Birjand, Iran	Palladium	05–20	Spherical	nd	86
<i>Galaxaura elongata</i>	Northwest Coast of Red Seashore	Gold	3.8–77.1	Spherical, rods, hexagonal and triangular	Antibacterial activity	106
<i>Laminaria japonica</i>	Local Seaweed Industry in Korea	Silver	31	Spherical to oval	Phytotoxicity and seedling growth assay	107
<i>Gelidium amansii</i>	Coastal Belt of South Korea	Silver	27–54	Spherical	Antibacterial and antibiofilm activity	108
<i>Padina tetrastrum</i> and <i>Turbinaria conoides</i>	Tuticorin Coast, Tamil Nadu, India	Zinc oxide	90–120	Spherical, pentagonal, hexagonal and triangles	Antibacterial activity	91
<i>Sargassum muticum</i>	Northwest Pacific Region, Iran	Zinc oxide	30–57	Hexagonal	Anti-angiogenesis and anti-apoptotic activity	92

nanocrystals of zinc sulfide and cadmium sulfide. The plant viruses are being proved to be safe for nanotechnology applications due to their structural and biochemical stability, ease of cultivation, non-toxicity and non-pathogenicity in animals and humans. In one study, low concentrations of tobacco mosaic virus (TMV) and bovine papilloma virus (BPV) were used as additives along with extracts of various plants *e.g.* *Nicotiana benthamiana*, *Avena sativa* and *Musa paradisiaca* etc.¹¹² The TMV and BPV not only helped in the reduction of size, but also significantly enhanced the numbers of the nanoparticles in

comparison to the non-virus control. Cao *et al.* employed red clover necrotic mosaic virus (RCNMV) for the synthesis of nanoparticles for the controlled delivery of doxorubicin drug for chemotherapy.¹¹³ The unique morphology of RCNMV and structural changes in response to divalent cations removal helps in doxorubicin infusion to the capsid through surface pore formation mechanism. Le *et al.* investigated the potential of potato virus X nanoparticles for the delivery of doxorubicin drug for cancer treatment.¹¹⁴ Potato virus X has the capability to synthesize elongated filamentous nanoparticles which exhibits



Table 4 A representative list of viruses used for the synthesis of nanoparticles and their applications

Algae	Nanoparticle type	Characterization		Applications	Reference
		Width (nm)	Morphology		
Tobacco mosaic virus (TMV)	Palladium	2.9–3.7	Multiwalled carbon nanotubes	Catalyst in Suzuki reaction and recyclable	115
Cucumber mosaic virus	Nanoassemblies	~29	Icosahedral	Anticancer drug delivery	110
Tobacco mosaic virus (TMV)	Gold	5	Spherical	Building block for chiral meta-molecules	109
Red clover necrotic mosaic virus	Nanocarriers	36	Icosahedral	Doxorubicin delivery	113
M13 virus	Titanium dioxide	20–40	Mesoporous nanowires	Photo-electrochemical properties	116
Potato virus X	Nanoconjugates	12	Filamentous rod shaped	Herceptin drug delivery in breast cancer therapy	117
Potato virus X	Nanocarriers	13	Helical	Doxorubicin delivery in cancer therapy	114
Hepatitis E virus	Nanoconjugates	27–34	Icosahedral	Cancer therapy	118

enhanced tumor homing and penetration power in comparison to spherical ones. However, synthesis of nanoparticles by viruses still faces various drawbacks such as involvement of host organism for protein expression, under-developed processes for synthesis and limited research on large scale application. Table 4 summarizes the results of recent reports on virus-based synthesis of metal nanoparticles and their applications.^{109–118}

3. Mechanism of nanoparticles synthesis using various bioreducing agents

In literature there are large number of reports which have discussed about the possible mechanistic aspects to explain the complex process of biomineralization of metal ions into nanoparticles. However, our current understanding of the mechanistic aspects is still very limited and need to be explored further. The biosynthesis of metal nanoparticles in microorganisms have been proposed to be dependent on three different mechanisms: reductase enzymes and proteins, exopoly-saccharide, and electron shuttle quinones.¹⁴

3.1 Role of enzyme and proteins

Majority of the studies have suggested possible involvement of enzymes and proteins as the main bioactive moiety which act as reducing and capping agent during the nanoparticles synthesis. Nanoparticles formation have been generally considered as an outcome of the microbes resistance to metal ions. Metal resistance has been seen in most of the bacteria and fungi. Microbes have adopted various defense mechanisms *viz.* reduction of metal ions, complex formation, precipitation, dissimilatory oxidation to fight against metal toxicity.¹¹⁹ Metal nanoparticles are produced *via* redox reactions which occur either intracellularly or extracellularly. Earlier reports have indicated the possible involvement of NADH-dependent nitrate reductases in metal bioreduction. In 2014, Karthik *et al.* proposed a possible mechanism for the bioreduction of silver ions into nanoparticles by using *Streptomyces* sp. LK3 at room temperature.⁴⁰

Their study concluded that the nitrate reductase enzyme of actinomycetes was responsible for the bioreduction process (Fig. 2). The culture not only demonstrated nitrate reduction to nitrite, but also showed reduction of nitrite to nitrogenous gases. The AgNPs were found to be stable for months without using any capping agents. Even no particle aggregation was observed in the mixture which further strengthens the stability of AgNPs. Their work provided an easy, cost-effective, and eco-friendly approach for the green synthesis of small size (5 nm) silver nanoparticles. In another study, Divya *et al.* demonstrated synthesis of monodispersed silver nanoparticles using the bacterial strain *Alcaligenes faecalis*.³⁵ This report also illustrated that the reducing agents such as NADH and NADH dependent reductases produced by culture in supernatant were mainly responsible for bio-mediated synthesis of silver nanoparticles. The investigators also suggested that the synthesized silver nanoparticles showed antimicrobial activity against urinary tract infection causing clinical isolates such as *Bacillus* sp., *E. coli*, *K. pneumoniae*, *S. aureus* and *C. albicans*. Recently, Hamedi *et al.* studied the synthesis of AgNPs using the cell free culture filtrates of *Fusarium oxysporum*⁶⁶ and results showed that the highest synthesis rate of nanoparticles was obtained during stationary phase when activity of extracellular enzyme nitrate reductase was maximum. Moreover, increase in C : N ratio resulted in the induction of nitrate reductase enzyme and synthesized AgNPs with small size and narrow size distribution.

Many researchers have investigated the role of conductive pili and cell surface proteins in transfer of electron resulting in extracellular reduction of metal ions.^{52,120,121} For *e.g.*, the biomineralization of uranium metal ions to uranium nanoparticles by *Geobacter sulfurreducens* has been reported by Cologgi *et al.* (2011).¹²⁰ The importance of pili (bacterial external appendages made up of pilin proteins) in extracellular reduction was validated by performing experiments under pilin-inducing and noninducing conditions. Astonishingly, in the pilin-deficient mutants, uranium nanoparticles were formed inside the periplasmic space, whereas in the pilin-supplemented strains, nanoparticles were produced extracellularly. Pilin expression significantly increased the rate of uranium biomineralization and prevented its periplasmic localization. Furthermore,






Fig. 2 Proposed mechanistic scheme of the bioreduction and stabilization of nanoscale particles by nitrate reductase enzyme.

another pioneer work in the area of uranium reduction explained the phenomenon of electron transport in actively respiring *Geobacter* spp. using conductive pili.¹²¹ It was concluded that pilin proteins in *Geobacter* were essential for the immobilization of uranium, c-cytochrome organization, and extracellular reduction of uranium. Kitching *et al.* demonstrated the one-pot synthesis of gold nanoparticles by purified cell surface protein of *Rhizopus oryzae*.⁵² This work elucidated the effect of cell surface protein on the size and morphology of AuNPs. It was concluded that different cell surface protein extraction methods could affect stability of protein and the AuNPs biosynthesis. Biosynthesized nanoparticles showed good stability and hemocompatibility for different biomedical applications.

Vasylevskiy *et al.* carried out an in-depth investigation of biomineralization process of silver ion at molecular level using *Geobacter sulfurreducens*.¹²² Vasylevskiy and his group explained that the reduction of Ag⁺ ion to Ag⁰ is an endergonic reaction, whereas aggregation to Ag_n clusters is an exergonic process which further leads to stable AgNPs synthesis. This hypothesis was based on various experiments conducted during AgNPs synthesis by photoinduced electron transfer through tetrapeptide/Ag⁺ solution (shown in Fig. 3). Electron transfer through tetrapeptide 1 containing histidine at N-terminal did not

generate AgNPs by photoinduction. Although, tyrosine amino acid present at C-terminal region of tetrapeptide 1 generated tyrosyl radicals and electrons, Ag⁺ ions attached to the histidine at N-terminal were not reduced to AgNPs. It was concluded that high binding energy of the imidazole side chain of histidine prevented the aggregation of Ag⁰ into Ag_n clusters and hence inhibited the synthesis of AgNP by photoinduction (Fig. 3, Scheme 1). But amino acids containing weaker Ag⁺ binding side chains such as aliphatic amines, amides, acids, alcohols, or alkyl groups could allow AgNPs synthesis by photoinduction. Therefore, histidine residue of the N-terminal region of tetrapeptide 1 was replaced by lysine, asparagine, aspartate, serine, and alanine, to generate the different tetrapeptides 2 A-E, respectively (Fig. 3). The addition of AgNO₃ solution to these tetrapeptides (2A–2E) synthesized AgNPs upon irradiation of the C-terminal tyrosine (Fig. 3, Scheme 2). Thus, it was concluded that successful production of AgNPs essentially requires a rapid exergonic aggregation of Ag⁰ into Ag_n clusters.

3.2 Role of electron shuttle quinones (or redox mediators)

During nanoparticles synthesis, electrons can be transferred *via* low molecular weight redox mediators like ubiquinol, NADH or oxygen/superoxide or by direct interaction between c-type cytochromes redox proteins and the metal ion.¹²³ Various literature






Fig. 3 Synthesis of silver nanoparticles (AgNPs) by electron transfer in peptides. Scheme (1) Inhibited synthesis of AgNPs by photoinduced electron transfer in tetrapeptide 1/ Ag^+ solution. Scheme (2) AgNPs synthesis in tetrapeptide 2A–E/ Ag^+ solution by photoinduced electron transfer [this figure has been adapted from ref. 122 with permission from Wiley].

reports have discussed the importance of both cytochromes and redox mediators in promoting extracellular synthesis of metal nanoparticles. Shi *et al.* explored the possibility of *Shewanella oneidensis* MR-1 utilizing ferric oxides minerals as terminal electron acceptors during anaerobic respiration,¹²⁴ and the role of c-type cytochromes in this electron transfer pathway. *S. oneidensis* MR-1 and related strains of metal-reducing *Shewanella* have evolved a metal-reducing machinery or Mtr pathway for transferring electrons across cell membranes to the surface. A molecular mechanism was proposed for the involvement of c-type cytochromes in transferring electrons from quinol at the

inner membrane (IM), through the periplasmic space (PS), and across the outer membrane (OM) to the metal oxide surface (Fe(III) oxide) (Fig. 4A). The protein components identified to date for the Mtr pathway include CymA, MtrA, MtrB, MtrC, and OmcA. A similar mechanism can be hypothesized for bacterial metal nanoparticles synthesis outside the bacterial cell surface (Fig. 4A). Shi *et al.* revealed that CymA is an inner-membrane tetraheme c-type cytochrome (c-Cyt), that belongs to the NapC/NrfH family of quinol dehydrogenases.¹²⁴ It was hypothesized that CymA oxidizes the quinol in the inner-membrane and transfers the electrons to MtrA either directly or indirectly





Fig. 4 (A) The proposed Metal-reducing (Mtr) extracellular electron transfer pathway of *S. oneidensis* MR-1 which is similar to bacterial metal nanoparticles synthesis outside the bacterial cell surface. CymA, MtrA, MtrC and OmcA are multiheme c-type cytochromes, while MtrB is a porin-like *trans*-outer membrane protein [this figure has been adapted from ref. 124 with permission from Frontiers]; (B) proposed mechanistic scheme of the biomineralization of gold ions by pullulan exopolysaccharide [this figure has been adapted from ref. 135 with permission from Elsevier].



through other periplasmic proteins. MtrA is a decaheme c-Cyt and observed to be embedded in the trans outer-membrane and porin like protein MtrB. Along with MtrB, MtrA transfers the electrons from the outer-membrane to the MtrC and OmcA located on the outermost surface. OmcA and MtrC are two outer-membrane decaheme c-Cyt which are translocated from the outer-membrane to cell surface by the bacterial type II secretion pathway. MtrC and OmcA function as terminal reducing agents and can bind to the surface of Fe(III) oxides and transfer electrons directly to these oxides through their exposed hemes part. MtrC and OmcA can also use the flavins secreted by *S. oneidensis* MR-1 cells as diffusible factors for reduction of Fe(III) oxides at faster rates. MtrC and OmcA can also serve as the terminal reducing agents for soluble forms of Fe(III) because of their broad redox potentials and extracellular location.

Earlier, Rodrigues *et al.* determined the molecular structure of NrfH of *Desulfovibrio vulgaris*, which is the only available molecular structure for the NapC/NrfH family of quinol dehydrogenases. This model proposes that quinol binds inside the pocket adjacent to heme 1 of NrfH of *D. vulgaris*, where quinol undergoes oxidation.^{125,126} The proximal axial ligand of NrfH of *D. vulgaris* contains a methionine residue (Met49) that is two residues downstream from the histidine residue of the CX₂CH motif for binding of heme 1, and an aspartate residue (Asp89) is at the position usually occupied by the distal axial ligand. However, Asp89 is not used for heme coordination but it binds to quinol.^{125,126} Later on, Hartshorne *et al.* provided the first molecular model of electron transfer across the bacterial outer-membrane.¹²⁷ MtrB is a trans outer-membrane spanning β -barrel protein that serves as a pocket to incorporate MtrA inside the membrane. MtrAB function as a trans outer-membrane delivery module for transfer of electrons to MtrC, which serves as an extracellular reductase. MtrA contains a signal peptide that targets the synthesized polypeptide to the periplasmic space *via* the bacterial secretory system. The MtrA polypeptides can be divided into two pentaheme domains, each of which shares sequence similarity with NrfB of *E. coli*.¹²⁸ When it is expressed in *E. coli*, the truncated MtrA having only one of its pentaheme domains is folded properly and contains five hemes, providing experimental evidence that MtrA contains two repetitive functional domains.¹²⁸ This type of heme arrangement help in rapid electron transfer from the heme groups of NrfB that form a molecular wire. Clarke *et al.* (2011) determined the molecular structure of MtrF, an MtrC homolog, and provided the molecular structural evidence in favour of terminal reducing agent for the outer-membrane c-Cyt of *S. oneidensis* MR-1 in Fe(III) oxide reduction.¹²⁹ Results revealed that MtrF is folded into four different domains: domains I (aa 49–186) and III (aa 319–473) each containing seven anti-parallel β -strands and folded together to form a split- β barrel structure, while domains II (aa 187–318) and IV (aa 474–641) each bind five tightly packed hemes. It was thought that domain II binds with solid-phase Fe(III) oxides by transferring electrons directly to the oxides *via* the solvent-exposed heme. Domain I and III are proposed to be involved in binding and reduction of flavins and soluble metals such as chelated Fe(III), while domain IV is involved in physical interaction with the MtrDE (MtrAB

homologs) complex and exchange electrons with MtrD. It should be mentioned that the overall shape of MtrF is very similar to that of OmcA;¹²⁹ which further confirms that MtrF and OmcA can fold in similar way. Like MtrC and OmcA, MtrF also reduces Fe(III) oxides and flavins.¹³⁰ Thus, the structural characterization of MtrF supported the fact that cell surface-bound c-Cyts MtrC, MtrF, and OmcA transfer electrons directly to the surface of Fe(III) oxides through their solvent-exposed hemes.

Later on, Ng *et al.* elucidated a technique to explain the role of c-type cytochromes in the extracellular synthesis of nanoparticles.¹³¹ In this technique, a mutant strain of *Shewanella oneidensis* lacking cytochrome genes (MtrC and OmcA) was used to perform silver nanoparticles synthesis. Nanoparticles produced by mutant strain were smaller in size and lesser in number as compared to wild-type strain of *S. oneidensis*. This indicated that c-type cytochromes help in transferring electrons to extracellular metal ions. Liu and co-authors demonstrated the direct involvement of outer membrane c-type cytochrome protein complexes (ombB, omaB and omcB) in extracellular reduction of Fe(III)-citrate and ferrihydrite using a metal-reducing bacterium *Geobacter sulfurreducens* PCA.^{132,133} The similar phenomenon of electron transfer *via* c-cytochromes was observed in another report on silver nanoparticles synthesis by *Geobacter sulfurreducens*.¹²² During this process, electrons generated through respiration were transported by Fe²⁺/hemes of c-cytochromes (Ppc) *via* periplasmic space to Fe³⁺/hemes of the outer membrane cytochromes (Omc). Subsequently, electrons were transferred from protein core of Omc to the surface attached Ag⁺ ions to synthesize AgNPs while oxidizing the cytochromes again to Fe³⁺/hemes (Fig. 4A). Overall, these reports concluded that the multiheme complexes help in electrons movement from the inner membrane to the cell wall (or outer membrane) *via* periplasm, and thus help in the extracellular reduction of metal ions into nanoparticles.

3.3 Role of exopolysaccharides

Bacterial exopolysaccharides (EPSs) are biomolecules which are secreted extracellularly and have different biological roles, such as environmental protection, surface adherence, and cell to cell interactions. EPSs have been explored as agents for greener production of numerous metal nanoparticles, since they have the capability to reduce metal ions to synthesize nanoparticles and stabilize them acting as capping agents.^{4,30} Kang *et al.* studied silver nanoparticles formation by exopolysaccharide in *Escherichia coli* biofilm and concluded that aldehyde and hemiacetal groups present in the exopolysaccharides act as the bioreducing agents.¹³⁴ FTIR and ¹³C nuclear magnetic resonance (NMR) spectroscopy results of EPS interactions with metal ion indicated that the hemiacetal groups of rhamnose sugars were involved in synthesis of silver nanoparticles. Moreover, the aldehyde groups in rhamnose and pyranose sugars were oxidized to carboxyl groups by silver ions. Choudhury *et al.* developed a strategy for the synthesis of gold nanoparticles using pullulan as reducing agent.¹³⁵ In-depth analysis of thermodynamic parameters further revealed that gold



nanoparticles synthesis followed first order kinetics and small size nanoparticles were formed at elevated temperature (100 °C). FTIR analysis clearly showed that the basic structure of pullulan remain unaffected during synthesis of gold nanoparticles by pullulan polymer, and α -1,4 and α -1,6 linkages of polymer were also intact even after the reaction. It was hypothesized that the biomineralization of gold ions was due to the oxidation of side chain aliphatic alcoholic groups of pullulan molecule. Thus, it may be concluded that the free CH₂OH groups of pure pullulan molecules were oxidized to COO⁻ carboxyl group, while simultaneous reduction of Au³⁺ to Au⁰ resulting in the formation of gold nanoparticles. Fig. 4B demonstrates the pictorial representation of biomineralization of gold ions by pullulan exopolysaccharide.

Similar observations were reported in another work while describing the synthesis of silver nanoparticles using *Ochrobactrum rhizosphaerae*, and deciphered that the active moiety responsible for synthesis and capping of silver nanoparticles was EPS.⁴ Later on characterization of the EPS by various biochemical techniques suggested that it is a glycoprotein (GLP) in nature. FTIR spectrum further revealed the involvement of various functional groups responsible for the reduction of metal ions to nano-colloidal solution. It was concluded that the free CH₂OH groups of GLP molecules were oxidized to carboxyl groups (COO⁻) with simultaneous reduction of Ag⁺ to Ag⁰ resulting in the formation of silver nanoparticles. In 2016, Raj *et al.* illustrated that EPS obtained from a marine bacterium, *Pseudomonas aeruginosa* JP-11, has the potential of forming spherical cadmium sulfide (CdS) nanoparticles which were in 20–40 nm diameter range.³³ Surface functionalization of EPS with sulphur groups enhanced the adsorption efficiency of cadmium metal ions. The sulphur groups are mostly preferred for functionalization due to their high stability constant and low solubility products. They easily attach with the cadmium ions in the aqueous solution and synthesize CdS nanoparticles. This work showcased that CdS nanoparticles synthesis using EPS also assists in cadmium metal detoxification from aqueous solution. In 2017, Yumei *et al.* reported synthesis of silver nanoparticles using EPS derived from *Arthrobacter* sp. B4.²⁹ Subsequent zeta potential and FTIR analysis revealed that the shift of C=O and OH absorption peaks in B4-EPS before and after the formation of silver nanoparticles was responsible for reducing Ag⁺ ion and leading to high stabilization of nanoparticles as capping agents. Furthermore, these nanoparticles showed high stability, excellent antibacterial activity, and low phytotoxicity.

The mechanistic aspects of nanoparticles synthesis by exopolysaccharides further need to be discussed in detail. The structure of EPSs is mainly composed of carbohydrates such as monomers of D-glucose, D-mannose, L-fucose, D-galactose, L-rhamnose, D-galacturonic acid, D-glucuronic acid, L-guluronic acid, D-mannuronic acid, N-acetyl-D-glucosamine, and N-acetyl-D-galactosamine, as well as noncarbohydrate components that confers an anionic nature to the EPSs such as carboxyl, phosphate, sulfate, and pyruvate substituents.^{136–139} In addition to providing the negative charge, these organic groups increase the lipophilicity of the EPSs and directly influence their

interaction with other polysaccharides and cations.¹³⁶ In general, it has been noted that once metal ions are in contact with EPSs that contain reducing sugars, they are chelated and then reduced and stabilized by various functional groups. Polyanionic groups are the best known chemical moieties to be involved in the reduction and stabilization of metal nanoparticles.¹⁴⁰ Moreover, electrostatic interactions between metal cationic ions and anionic groups such as carboxylic and phosphoric functional groups of EPS have been mentioned to be an advantage for the synthesis of metal nanoparticles.¹⁴¹ Among these functional groups, hydroxyl, carboxyl, phosphoric, hemiacetal, and amino end groups have been proposed to reduce metal ions from the precursor salts to obtain the respective nanoparticles.¹⁴² In relation with the above, hydroxyl groups have been attributed the ability to coordinate with metal ions.¹⁴³ In fact, during the reducing process, oxidation of hydroxyl groups to form carbonyl groups as well as oxidation of alcoholic and aldehydic groups to form carboxylic groups has been reported to be an important factor during synthesis of metal nanoparticles.¹⁴⁴ Thus, in relation to the EPSs described in this study, the structure of xanthan gum has been described to be helical with many hydroxyl groups that can carry out reduction of ions. In addition, this structure creates a network by hydrogen bonding in which nanoparticles stabilize.¹⁴⁵ Further, xanthan gum has negative charge due to acetyl groups and pyruvic acid linked with mannose, and provides this charge to nanoparticle surface creating a steric repulsion among them.¹⁴⁶ Dextran, is useful in the synthesis of metal nanoparticles since their hydroxyl, ketone, aldehydes, and carboxyl groups interact and allow the reduction of Ag⁺ ions to form Ag-NPs, preventing their agglomeration as well.¹⁴⁷ At this point, it was mentioned that oxygen from dextran functional groups can donate their pair of electrons to gold ions thereby producing Au-NPs.¹⁴⁸ As it is well known, dextran is rich in hydroxyl groups that can interact with magnetic nanoparticles by hydrogen bonds stabilizing them.¹⁴⁹ For curdlan, the carboxylic groups of curdlan derivatives such as carboxylic curdlan and carboxymethyl curdlan have the ability to adsorb metal ions by electrostatic attractive forces. These functional groups reduce the metal ions, and the necessary nucleation is created to form stabilized clusters during synthesis of AuNPs and AgNPs.^{150,151}

4. Large scale production of biomediated nanoparticles

Microbial fermentation represents state of the art approach for large-scale production of nanoscale structures of different metals. In recent years, researchers have explored large-scale synthesis of nanoparticles using biogenic routes with a narrow size distribution.^{152,153} In 2010, Moon and his group first time reported large scale production of magnetic and metal-substituted magnetic nanoparticles using *Thermoanaerobacter* sp. TOR-39.¹⁵⁴ This report concluded that magnetic nanoparticles production can be obtained in huge quantities at low cost, similar to traditional chemical synthesis. At the end, about 1 kg (wet weight) of Zn-substituted magnetites were



obtained from 30 L fermentations. The magnetic nanoparticles have become focus of recent research as they are promising candidate for magnetic resonance imaging, bioremediation, data storage, catalysis biosensors development, and they can be manipulated very easily under magnetic field influence. In another report, Moon *et al.* employed the same thermophilic strain *Thermoanaerobacter* sp. TOR-39 for the extracellular synthesis of cadmium sulfide (CdS) nanoparticles.¹⁵⁵ The size of CdS crystallites was less than 10 nm and process was easily scalable up to 24 L. Various factors such as biomass concentration, dosing amount, type of precursors used, and the basal medium composition were found to be crucial for producing tailor-made nanoparticles. Later on, Moon *et al.* elucidated synthesis of semiconducting zinc sulfide (ZnS) nanoparticles in lab-scale reactor of 24 L capacity using an anaerobic thermophilic metal-reducing bacterium *Thermoanaerobacter* sp. X513.¹⁵² Production of ZnS nanoparticles was scalable, reproducible and controllable (within 2–10 nm range) from 10 mL to 24 L with yields of 5 g per L per month. More recently, Moon *et al.* demonstrated the scale-up of nanoparticles synthesis from lab scale to pilot-plant level using same bacterium.¹⁵⁶ This work investigated the scalability of bacteria mediated ZnS nanoparticles production in 100 L and 900 L scale bioreactors. Repeated 100 L batches using fresh or recycled media produced ZnS nanoparticles with high reproducibility in crystalline size of 2 nm and yields of approximately 0.5 g L⁻¹ which were close to the small-scale batches. The cultivation at 900 L scale yielded around 320 g ZnS nanoparticles powder and this amount was sufficient for the synthesis of ZnS thin film with thickness of 120 nm over 0.5 m width and 13 km length. In another study, Ramos-Ruiz *et al.* discussed the potential of upflow anaerobic sludge bed reactors for continuous conversion of toxic tellurite oxyanions (Te^{IV}) to non-toxic recoverable tellurium (Te⁰) nanoparticles using methanogenic microbial consortium.¹⁵³ This group also evaluated the effect of redox mediating flavonoid compound, riboflavin (RF), with the aim of increasing the reduction of tellurite oxyanions. The presence of riboflavin mediator enhanced the conversion rate of tellurite by approximately 11-fold. This work elucidated that the methanogenic anaerobic granular sludge can be adopted as a bioreactor technology for the continuous production of tellurium nanoparticles in direct recoverable mode (Fig. 5A). Moreover, the sludge was able to sustain the reduction of high loads of toxic tellurite oxyanions. With respect to large-scale production, the fact that only few reports are available on bioreactor cultivation strategies for biosynthesis in last six years is not a good finding, as these strategies are essential for obtaining higher productivity of nanoparticles synthesis. These are indeed important for large-scale level production and thus need to be further investigated.

5. Advantages and limitations of biological methods in nanoparticles synthesis

There have been tremendous developments in the field of microorganism produced nanoparticles and their applications

over the last decade. The biosynthesis of nanoparticles has numerous advantages such as benign and eco-friendly production, cost-effectiveness and the biocompatibility of synthesized nanoparticles.¹⁴ As opposed to physicochemical processes, biosynthesized nanoparticles are free from toxic chemical contaminants which is essentially a desirable trait for biomedical applications.⁷ The another benefit of the biogenic route of synthesis is that it does not require an additional step of capping or attachment of bioactive compounds to the nanoparticle surface to generate stable and pharmacological active particles which is otherwise essential in physicochemical synthesis.^{4,29,40} Furthermore, the time required for biosynthesis of nanoparticles is much lesser than the physicochemical methods. For example, Arsiya *et al.* demonstrated one-step biosynthesis of palladium nanoparticles using *Chlorella vulgaris*.⁸⁶ The reduction of palladium ions into nanoparticles was achieved within 10 minutes at room temperature. The FTIR analysis of *Chlorella vulgaris* extract revealed that polyol and amide groups present in extract act as reducing and stabilizing agents. Several other investigators have discovered rapid biosynthetic procedures with high nanoparticles yield using different algal extracts. For example, silver nanoparticles were synthesized by algal extracts within 2 min,¹⁰⁶ 15 min (ref. 104) and 1 h.¹⁰³ Gold nanoparticles were also formed within 5 min (ref. 106) and 10 min (ref. 95) highlighting the importance of nanoparticles synthesis using biogenic agents. In spite of various advantages offered by the biological route for the synthesis, the polydispersity and size of the nanoparticles are still big and challenging issues. Further, much work is needed to improve the efficiency of synthesis, the control of particle size and morphology. Thus, several current reports have developed a stable system for nanoparticles biosynthesis with monodispersity in size and shape. Size and shape of metal nanoparticles could be controlled by either optimizing the process parameters or modifying these parameters (Fig. 5B). For example, Hamedi *et al.* demonstrated synthesis of highly monodispersed silver nanoparticles using *F. oxysporum* by altering the process conditions such as incubation time, temperature, metal salt concentration and C : N ratio.⁶⁶ The increase in C : N ratio resulted in synthesis of small size AgNPs with high monodispersity and productivity. In 2018, Domany *et al.* synthesized stable gold nanoparticles with moderate dispersity using *Pleurotus ostreatus* extracellular filtrate.⁵⁴ The AuNPs synthesis rate was found to increase with the increase in HAuCl₄ salt concentration, incubation time and agitation, whereas pH and temperature showed negative relation with AuNPs synthesis rate which indicates higher productivity at lower values.

In case of microbes, modification in pH leads to alteration in the overall charge of bioactive molecules, which in turn facilitates their binding affinity and hence biomineralization of metal ions into nanoparticles. For example, Yumei *et al.* showed that *Arthrobacter* sp. promotes synthesis of silver nanoparticles at pH 7.0 and 8.0, whereas no AgNPs synthesis was recorded below pH 5.0 due to strong electrostatic repulsion between silver ion and EPS in acidic conditions.²⁹ Even at higher pH (above 8), no AgNPs formation was observed due to high





Fig. 5 (A) Continuous reduction of toxic tellurite (Te^{IV}) oxyanions into recoverable tellurium nanoparticles using anaerobic sludge reactor [this figure has been adapted from ref. 153 with permission from Elsevier]; (B) parameters for producing monodispersed, stable, and high-yield biological nanoparticles [this figure has been adapted from ref. 16 with permission from Elsevier].

electronegativity under alkaline conditions, which is not favourable for reduction of Ag^+ ion due to the presence of $-\text{COO}^-$ group. Furthermore, process parameters could also affect the shape and yield of nanoparticles. Ramanathan *et al.* demonstrated that spherical shaped silver nanoparticles (AgNPs) of small size were synthesized at optimum growth

temperature of 20°C using *Morganella psychrotolerans*,²⁸ whereas silver nanoplates of large size were observed at growth temperature of 4°C . Although there are few reports on process parameter optimization, it is clear from the results that optimizing these variables can solve the issue of polydispersity and production yield of nanoparticles. This demands further



investigation on bio-mediated synthesis of nanoparticles for their production with high efficiency.

For efficient bio-synthesis of metallic nanoparticles, a number of controlling factors are involved in the nucleation and subsequent formation of stabilized nanoparticles. These factors include pH, reactant concentrations, reaction time, and temperature (as discussed earlier). Apart from optimizing these parameters, the use of biofilms is another prospective approach for efficient biosynthesis of nanoparticles.¹¹⁹ Biofilms have recently been recognized as the most active growth mode of bacteria.¹⁵⁷ Biofilms exhibit various interesting properties such as catalyzing activity, highly reducing matrix and ability to control electrochemical reactions which provide a favourable environment for easy and efficient synthesis of nanoparticles than planktonic cells at forming nanoparticles.¹⁵⁸ Moreover, the protective nature of biofilms with diffusion limitation for outside materials, keeps the entire synthesis process free from contamination; overall, this makes it a promising approach for biosynthesis of nanoparticles in aqueous systems.¹⁵⁹ Nanoparticles synthesis in biofilms offers additional advantages, such as high biomass concentrations and large surface areas, which can lead to more efficient and scalable biosynthesis. Biofilms have up to 600 times higher metal resistance properties than their planktonic counterparts¹⁶⁰ and can catalyze electrochemical redox reactions by providing an appropriate environment with natural reducing agents such as proteins, peptides, and heterocyclic compounds for metal reduction to nanoparticles.^{159,161} However, there has been very limited work on nanoparticles synthesis in biofilms and little is known about the stabilizing mechanism of nanoparticles in biofilms. Therefore, a thorough understanding of the molecular mechanism of nanoparticles synthesis in biofilms as well as their planktonic counterparts would help future researchers to develop more robust microbial systems for rapid and optimized biosynthesis of nanoparticles with desired sizes and shapes. Based on the mechanisms of metal reduction in bacterial biofilms, genetic modification of bacterial strains can be designed to obtain controlled sizes and shapes of nanoparticles and optimize production with high yield.¹⁶²

Furthermore, the conversion of metal into nanoparticles also brings toxicity issues. Several reports have mentioned adverse effects of these nanomaterials on the biological systems and cellular components. Cytotoxicity of nanoparticles depends on various factors such as their size, shape, capping agent, density of nanoparticles, and the type of pathogens against which their toxicity is evaluated.¹⁶³ Nanoparticles synthesized from non-biological route are generally more toxic than those synthesized from the biological route. Some pathogens are more prone to nanoparticles, specially AgNPs than others due to the presence of both the Ag⁺ ions and NPs. They slowly envelope the microbial cell and enter inside it inhibiting their essential metabolic functions. Nanoparticles are comparatively more toxic than bulk materials. They are toxic at cellular, subcellular and molecular levels.¹⁶⁴ There are several reasons for the cytotoxicity of nanoparticles such as physicochemical properties, contamination with toxic element, small size, high surface charge and free radical species generation. Oxidative stress and

lipid peroxidation have been observed in fish brain tissue on exposure to nanoparticles.¹⁶⁵ The cytotoxicity by nanoparticles is thought to be generated through reactive oxygen species (ROS) as a result of which a decrease in glutathione levels and an increase in free radicals occur. Nanoparticles have large surface area which provide a better contact with microbes. Therefore, these nanoparticles are able to penetrate the cell membrane or attach to the cell surface based on their particle size.¹⁶⁶ Moreover, they were observed to be highly toxic to the bacterial strains and their antibacterial efficacy is increased with the decrease in particle size. Carlson *et al.* have demonstrated an increase in ROS generation for 15 nm hydrocarbon coated AgNPs as compared to 55 nm.¹⁶⁷ It has been observed by Liu *et al.* that 5 nm AgNPs were more toxic than 20 and 50 nm nanoparticles to four cell lines, namely, A549, HePG2, MCF-7 and SGC-7901.¹⁶⁸ Till date, there have been extensive research on nanoparticles toxicity in order to explain their mechanism of action, and three different mechanisms have been devised so far which include cell wall and membrane damage, intracellular penetration and molecular damage, and oxidative stress. These mode of action have been discussed in detail in next section.

The toxicity concern of nanoparticles can be suitably reduced by coating these nanoparticles with biocompatible agents. Although the main role of coating/capping is to stabilize that nanoparticles and prevent agglomeration, but the biocompatible nature also makes it suitable for various biomedical applications.¹⁶³ In green synthesis, stabilization of the nanoparticles is achieved by the biocompatible material only, and hence the toxicity issue is reduced in most of the cases. In 2012, one report suggested that the stabilization of AgNPs by different polymer surfactants reduces the toxicity of AgNPs against mouse skin fibroblasts (L929), human hepatocarcinoma cells (HepG2), and mouse monocyte macrophages (J774A1).¹⁶⁹ Polymer capped AgNPs at a concentration of 1.5 ppm showed hemocompatible nature. It is a well known fact that the materials with a hemolysis ratio less than 5% are generally regarded as hemocompatible and safe.^{163,169} Biosynthesis using polymer *i.e.* glucan resulted in a glucan capped spherical AgNPs of size 2.44 nm.¹⁷⁰ These nanoparticles showed only 0.68% hemolysis to human red blood cells (RBCs) at its LD₅₀ dosage. Thus, AgNPs–glucan conjugates were observed to be biocompatible with human RBCs at their LD₅₀ dosage. In a similar study, polysaccharide capped AgNPs of size 2.78 nm were synthesized using a hetero-polysaccharide isolated from *Lentinus squarrosulus* (Mont.).¹⁷¹ These nanoparticles also showed compatible nature with human RBCs at its LD₅₀ dosage. Thus, the biocompatibility obtained through green synthesis route suggests that it is possible to use nanoparticles in varying field of biomedical application.

6. Mechanism of antimicrobial action

The interaction of nanoparticles with microorganisms starts with adhesion of nanoparticles on the microbial cell wall and membrane, and it is based on electrostatic attraction between the negatively charged microbial cell membrane and positively or less negatively charged nanoparticles.¹⁷² The interaction of



nanoparticles with bacterial cells is also demonstrated by a significant drop in zeta potential of cell surface in both Gram-positive and Gram-negative bacteria.^{173,174} After adhesion, morphological changes in the membrane structure are induced by the nanoparticles, and thereby resulting in disruption of membrane permeability and respiratory functions through membrane depolarization, and ultimately disruption of the cell structure and cell death.¹⁷⁵ As a result of the disruption of the cell structure, the cellular components including enzymes, proteins, DNA, metabolites start leaking into the environment.^{175–177} Therefore, this degeneration of the cell wall by the nanoparticle attachment is believed to be first mechanism of the antimicrobial action.¹⁷⁸ Moreover, nanoparticles have been reported to cause irregular pit formations on the cell wall, which further help the nanoparticles to enter into the periplasmic space and finally inside the cell.¹⁷⁹ After the interaction of nanoparticles with bacterial cells, peripheral damages and dense cavities on the cell surface can be observed by advanced imaging techniques such as transmission electron microscopy (TEM), scanning electron microscopy (SEM) and atomic force microscopy (AFM).¹⁸⁰ Gahlawat *et al.* investigated the morphological changes in bacterial cell caused by AgNPs by scanning electron microscopy (SEM).⁴ The untreated bacterial cells demonstrated smooth morphology and original structures, whereas the cells treated with AgNP for 5 h showed pores and cavities on the cell membrane and lost their membrane integrity and the original morphology. They also reported the cell lysis and leakage of intracellular contents from the AgNP treated bacterial cells using SEM.⁴ In addition, it is thought that nanoparticles can also interact with proteins on the outer surface, form complexes with oxygen, phosphorous, nitrogen or sulphur atom containing electron donors, and cause irreversible damages in the cell wall.¹⁸¹ The interaction of protein thiol groups with silver ions and AgNPs is well-understood, and thiol groups in the enzymes of bacterial respiratory chain have been found to be possible sites for Ag⁺ ion binding.¹⁸² In another study, it was elucidated that the interaction of nanoparticles with sulphur containing membrane-bound proteins and enzymes led to inactivation of these molecules.¹⁸³ McQuillan and Shaw (2014) proposed another possible mechanism in which Ag⁺ released from AgNPs may enter inside the cell by cation selective membrane transport proteins called porins, and cause damage to cellular machine.¹⁸⁴

After disintegrating cell membrane and cell wall, nanoparticles can penetrate inside the cell and affect crucial functions of the cell by interacting with DNA and proteins.¹⁸⁵ One of the proposed mechanism for antimicrobial activity of AgNPs is based on silver ion release from the nanoparticles, which has an adverse effect on both DNA and proteins.¹⁸⁶ Feng *et al.* reported that silver ions led to deformation of the bacterial DNA from the natural relaxed state to a condensed state in which the DNA loses its replication ability.¹⁸⁷ Moreover, Energy Dispersive X-ray Analysis demonstrated the sulphur existence which indicates that silver ions interacted with thiol groups of proteins and resulted in inactivation of enzymatic activity. Besides this conformational change in DNA, nanoparticles can also cause degradation and/or denaturation of DNA. Toxicity by

nanoparticles is generally induced by the formation of free radicals, such as ROS.¹⁸⁸ If the ROS is produced it may cause membrane disruption and disturb the permeability. The ROS include superoxide (O₂[−]), hydroxyl (·OH), peroxy (RCOO·), hypochlorous acid (HOCl), and hydrogen peroxide (H₂O₂). These free radicals damage the cell wall and biomolecules such as proteins, enzymes, lipids and DNA. DNA damages include deletions, additions, mutations, single-breaks, double-strand breaks, and cross-linking with proteins. In this regard, Das *et al.* evaluated the ROS-mediated antibacterial activity of AgNPs against multidrug resistant *E. coli* and *S. aureus*, and found that ROS generation significantly contributed to the antibacterial action.¹⁸⁹ High ROS levels caused the membrane damage by increasing the permeability, which ultimately resulted in disruption of electron transport chain and leakage of the intracellular content. It is also possible that ROS generation mediated by Ag⁺ ions released from AgNPs can cause dysfunction of the bacterial electron transport chain and proton motive force as a result of inhibition of enzymes involved in the reactions.¹⁹⁰ In addition to disruption of membrane functions, Soo-Hwan *et al.* found that AgNP-mediated ROS generation caused protein leakage by increasing the membrane permeability.¹⁹¹ Protein leakage from the cells treated with AgNPs finally resulted in cell death.

7. Future perspectives

In recent years, metal nanoparticles have been studied widely for various biomedical, bioremediation and biosensor applications because of their remarkable antibacterial, antioxidant and optical properties, large surface area to volume ratio and higher efficacy. The synthesis of metal nanoparticles by biological mode has evolved as an important branch of nanobiotechnology, and bio-agents serves as potential nanofactories for the production of nanomaterials. However, there are certain gaps and limitations in successful production of these nanoparticles which need to be sorted out by the scientific community. One of the major limitation in biomediated synthesis is complete and thorough understanding of mechanistic aspects of biofabrication of nanoparticles. Although there are reports in literature on identification and isolation of bioactive moiety responsible for biomineralization of metal ions using biological extracts, much detailed analysis of biochemical pathway is further needed for the development of tailor-made nanoparticles. Especially for biomedical purposes, it is indispensable to understand how active moieties from various biological resources bind to the nanoparticle surface to provide stability, and to synthesize nanoparticles with higher biocompatibility. Large-scale production is another major bottleneck in the development and commercialization of biocompatible nanostructures with controlled sizes and shapes. Recently, researchers have focussed on large-scale cultivation methods for nanoparticles synthesis which are scalable and reproducible with narrow size distribution. But these bulk cultivation methods for bio-nanomaterials and downstream processing techniques need to be improved further. Large scale cultivation of nanoparticles is generally hampered by the factors of high



cost, high energy requirement, polydispersity and low nanoparticles yield. The production of nanoparticles at room temperatures using natural active biomolecules without any reducing agents would make large-scale fermentation more cost-effective and energy sustainable. Stable production of monodispersed nanoparticles with high yield could be achieved by optimizing various process parameters (pH, temperature, contact time, mixing ratio, salt concentration) and altering the overall charge on functional molecules. Apart from this, issues related to the biomedical applications *viz.* the distribution profile, release kinetics and clearance of nanostructures *in vivo* need to be sorted out. In-depth evaluation of the biocompatibility and bioavailability of nanomaterials is still in stage of infancy and considerable research efforts are needed in this area. The collaborative research on fermentation process development along with understanding of mechanistic aspects, scale-up and exploration of other biological agents could expedite the process of cost-effective tailor-made synthesis of nanomaterials.

Conflicts of interest

Authors declare that they have no conflicts of interest.

Acknowledgements

All authors duly acknowledge the Council of Scientific and Industrial Research – Institute of Microbial Technology (CSIR-IMTECH) for providing all necessary facilities. One of the authors (Dr. Geeta Gahlawat) acknowledges the University Grants Commission, Government of India for providing Dr. D. S. Kothari fellowship for her research work.

References

- 1 K. N. Thakkar, S. S. Mhatre and R. Y. Parikh, *Nanomedicine*, 2010, **6**, 257–262.
- 2 K. B. Narayanan and N. Sakthivel, *Adv. Colloid Interface Sci.*, 2010, **156**, 1–13.
- 3 A. Albanese, P. S. Tang and W. C. Chan, *Annu. Rev. Biomed. Eng.*, 2012, **14**, 1–16.
- 4 G. Gahlawat, S. Shikha, B. S. Chaddha, S. R. Chaudhuri, S. Mayilraj and A. R. Choudhury, *Microb. Cell Fact.*, 2016, **15**, 25.
- 5 C. Burda, X. Chen, R. Narayanan and M. A. El-Sayed, *Chem. Rev.*, 2005, **105**, 1025–1102.
- 6 M.-C. Daniel and D. Astruc, *Chem. Rev.*, 2004, **104**, 293–346.
- 7 S. Ahmed, M. Ahmad, B. L. Swami and S. Ikram, *J. Adv. Res.*, 2016, **7**, 17–28.
- 8 U. Shedbalkar, R. Singh, S. Wadhvani, S. Gaidhani and B. Chopade, *Adv. Colloid Interface Sci.*, 2014, **209**, 40–48.
- 9 B. I. Kharisov, O. V. Kharissova and U. Ortiz-Mendez, *CRC concise encyclopedia of nanotechnology*, CRC Press, 2016.
- 10 D. Nath and P. Banerjee, *Environ. Toxicol. Pharmacol.*, 2013, **36**, 997–1014.
- 11 M. Shah, D. Fawcett, S. Sharma, S. Tripathy and G. Poinern, *Materials*, 2015, **8**, 7278–7308.
- 12 H. You, S. Yang, B. Ding and H. Yang, *Chem. Soc. Rev.*, 2013, **42**, 2880–2904.
- 13 N. Kulkarni and U. Muddapur, *J. Nanotechnol.*, 2014, **2014**, 1–8.
- 14 P. Singh, Y.-J. Kim, D. Zhang and D.-C. Yang, *Trends Biotechnol.*, 2016, **34**, 588–599.
- 15 S. Dhuper, D. Panda and P. Nayak, *Nano Trends: J Nanotech. App.*, 2012, **13**, 16–22.
- 16 M. A. Faramarzi and A. Sadighi, *Adv. Colloid Interface Sci.*, 2013, **189**, 1–20.
- 17 S. Irvani, *Int. Sch. Res. Notices*, 2014, **2014**, 1–18.
- 18 T. Beveridge and R. Murray, *J. Bacteriol.*, 1980, **141**, 876–887.
- 19 T. Klaus-Joerger, R. Joerger, E. Olsson and C.-G. Granqvist, *Trends Biotechnol.*, 2001, **19**, 15–20.
- 20 S. K. Srivastava and M. Constanti, *J. Nanopart. Res.*, 2012, **14**, 831.
- 21 V. L. Das, R. Thomas, R. T. Varghese, E. Soniya, J. Mathew and E. Radhakrishnan, *3 Biotech*, 2014, **4**, 121–126.
- 22 R. R. Kulkarni, N. S. Shaiwale, D. N. Deobagkar and D. D. Deobagkar, *Int. J. Nanomed.*, 2015, **10**, 963.
- 23 E. Ahmed, S. Kalathil, L. Shi, O. Alharbi and P. Wang, *J. Saudi Chem. Soc.*, 2018, **22**, 919–929.
- 24 E. Zonaro, E. Piacenza, A. Presentato, F. Monti, R. Dell'Anna, S. Lampis and G. Vallini, *Microb. Cell Fact.*, 2017, **16**, 215.
- 25 B. Srinath, K. Namratha and K. Byrappa, *Adv. Sci. Lett.*, 2018, **24**, 5942–5946.
- 26 M. Saravanan, S. K. Barik, D. Mubarak Ali, P. Prakash and A. Pugazhendhi, *Microb. Pathog.*, 2018, **116**, 221–226.
- 27 N. I. Hulkoti and T. Taranath, *Colloids Surf., B*, 2014, **121**, 474–483.
- 28 R. Ramanathan, A. P. O'Mullane, R. Y. Parikh, P. M. Smooker, S. K. Bhargava and V. Bansal, *Langmuir*, 2010, **27**, 714–719.
- 29 L. Yumei, L. Yamei, L. Qiang and B. Jie, *J. Nanomater.*, 2017, **2017**, 1–8.
- 30 A. Malhotra, K. Dolma, N. Kaur, Y. S. Rathore, S. Mayilraj and A. R. Choudhury, *Bioresour. Technol.*, 2013, **142**, 727–731.
- 31 H. Kaur, K. Dolma, N. Kaur, A. Malhotra, N. Kumar, P. Dixit, D. Sharma, S. Mayilraj and A. R. Choudhury, *Biotechnol. Bioprocess Eng.*, 2015, **20**, 51–57.
- 32 A. Mehta, C. Sidhu, A. K. Pinnaka and A. R. Choudhury, *PLoS One*, 2014, **9**, e98798.
- 33 R. Raj, K. Dalei, J. Chakraborty and S. Das, *J. Colloid Interface Sci.*, 2016, **462**, 166–175.
- 34 S. Sunkar and C. V. Nachiyar, *Asian Pac. J. Trop. Biomed.*, 2012, **2**, 953–959.
- 35 M. Divya, S. K. George, H. Saqib and S. Joseph, *Biocatal. Agric. Biotechnol.*, 2019, **18**, 101037.
- 36 A. Müller, D. Behnlian, E. Walz, V. Gräf, L. Hogeckamp and R. Greiner, *Biocatal. Agric. Biotechnol.*, 2016, **6**, 107–115.
- 37 M. M. Naik, M. S. Prabhu, S. N. Samant, P. M. Naik and S. Shirodkar, *Thalassas: an International Journal of Marine Sciences*, 2017, **33**, 73–80.
- 38 M. Manimaran and K. Kannabiran, *Lett. Appl. Microbiol.*, 2017, **64**, 401–408.



- 39 S. Otari, R. Patil, N. Nadaf, S. Ghosh and S. Pawar, *Mater. Lett.*, 2012, **72**, 92–94.
- 40 L. Karthik, G. Kumar, A. V. Kirthi, A. Rahuman and K. B. Rao, *Bioprocess Biosyst. Eng.*, 2014, **37**, 261–267.
- 41 B. Buszewski, V. Railean-Plugaru, P. Pomastowski, K. Rafińska, M. Szultka-Mlynska, P. Golinska, M. Wypij, D. Laskowski and H. Dahm, *J. Microbiol., Immunol. Infect.*, 2016, **20**, 1–10.
- 42 H. M. Abd-Elnaby, G. M. Abo-Elala, U. M. Abdel-Raouf and M. M. Hamed, *Egypt. J. Aquat. Res.*, 2016, **42**, 301–312.
- 43 V. Ranjitha and V. R. Rai, *3 Biotech*, 2017, **7**, 299.
- 44 E. Saad, S. S. Salem, A. Fouda, M. A. Awad, M. S. El-Gamal and A. M. Abdo, *J. Radiat. Res. Appl. Sci.*, 2018, **30**, 1–9.
- 45 S. Otari, R. Patil, N. Nadaf, S. Ghosh and S. Pawar, *Environ. Sci. Pollut. Res.*, 2014, **21**, 1503–1513.
- 46 N. Mara Silva-Vinhote, N. E. D. Caballero, T. de Amorim Silva, P. V. Quelemes, A. R. de Araujo, A. C. M. de Moraes, A. L. dos Santos Câmara, J. P. F. Longo, R. B. Azevedo and D. A. da Silva, *Afr. J. Biotechnol.*, 2017, **16**, 2072–2082.
- 47 M. Wypij, J. Czarnecka, M. Świecimska, H. Dahm, M. Rai and P. Golinska, *World J. Microbiol. Biotechnol.*, 2018, **34**, 23.
- 48 A. Bhargava, N. Jain, M. A. Khan, V. Pareek, R. V. Dilip and J. Panwar, *J. Environ. Manage.*, 2016, **183**, 22–32.
- 49 A. Mishra, M. Kumari, S. Pandey, V. Chaudhry, K. Gupta and C. Nautiyal, *Bioresour. Technol.*, 2014, **166**, 235–242.
- 50 R. P. Metuku, S. Pabba, S. Burra, K. Gudikandula and M. S. Charya, *3 Biotech*, 2014, **4**, 227–234.
- 51 S. Rajput, R. Werezuk, R. M. Lange and M. T. McDermott, *Langmuir*, 2016, **32**, 8688–8697.
- 52 M. Kitching, P. Choudhary, S. Inguva, Y. Guo, M. Ramani, S. K. Das and E. Marsili, *Enzyme Microb. Technol.*, 2016, **95**, 76–84.
- 53 P. Suryavanshi, R. Pandit, A. Gade, M. Derita, S. Zachino and M. Rai, *LWT-Food Sci. Technol.*, 2017, **81**, 188–194.
- 54 E. B. El Domany, T. M. Essam, A. E. Ahmed and A. A. Farghali, *J. Appl. Pharm. Sci.*, 2018, **8**, 119–128.
- 55 M. Hamad, *Int. J. Environ. Sci. Technol.*, 2018, 1–10.
- 56 S. V. Ganachari, R. Bhat, R. Deshpande and A. Venkataraman, *BioNanoScience*, 2012, **2**, 316–321.
- 57 S. Roy, T. Mukherjee, S. Chakraborty and T. K. Das, *Dig. J. Nanomater. Biostruct.*, 2013, **8**, 197–205.
- 58 J. N. Thakker, P. Dalwadi and P. C. Dhandhukia, *ISRN Biotechnol.*, 2012, 2013.
- 59 A. S. Bhadwal, R. Tripathi, R. K. Gupta, N. Kumar, R. Singh and A. Shrivastav, *RSC Adv.*, 2014, **4**, 9484–9490.
- 60 M. Castro, L. Cottet and A. Castillo, *Mater. Lett.*, 2014, **115**, 42–44.
- 61 P. K. Kar, S. Murmu, S. Saha, V. Tandon and K. Acharya, *PLoS One*, 2014, **9**, e84693.
- 62 G. Baskar, J. Chandhuru, K. S. Fahad, A. Praveen, M. Chamundeeswari and T. Muthukumar, *J. Mater. Sci.: Mater. Med.*, 2015, **26**, 43.
- 63 P. Ramalingam, S. Muthukrishnan and P. Thangaraj, *J. Nanosci. Nanoeng.*, 2015, **1**, 241–247.
- 64 D. Amerasan, T. Nataraj, K. Murugan, C. Panneerselvam, P. Madhiyazhagan, M. Nicoletti and G. Benelli, *J. Pest Sci.*, 2016, **89**, 249–256.
- 65 M. Guilger, T. Pasquoto-Stigliani, N. Bilesky-Jose, R. Grillo, P. Abhilash, L. F. Fraceto and R. De Lima, *Sci. Rep.*, 2017, **7**, 44421.
- 66 S. Hamed, M. Ghaseminezhad, S. Shokrollahzadeh and S. A. Shojasadati, *Artif. Cells, Nanomed., Biotechnol.*, 2017, **45**, 1588–1596.
- 67 M. Apte, D. Sambre, S. Gaikawad, S. Joshi, A. Bankar, A. R. Kumar and S. Zinjarde, *AMB Express*, 2013, **3**, 32.
- 68 S. R. Waghmare, M. N. Mulla, S. R. Marathe and K. D. Sonawane, *3 Biotech*, 2015, **5**, 33–38.
- 69 F. Elahian, S. Reisi, A. Shahidi and S. A. Mirzaei, *Nanomedicine*, 2017, **13**, 853–861.
- 70 M. Eugenio, N. Müller, S. Frases, R. Almeida-Paes, L. M. T. Lima, L. Lemgruber, M. Farina, W. de Souza and C. Sant'Anna, *RSC Adv.*, 2016, **6**, 9893–9904.
- 71 M. Sriramulu and S. Sumathi, *Adv. Nat. Sci.: Nanosci. Nanotechnol.*, 2018, **9**, 025018.
- 72 S. Seshadri, K. Saranya and M. Kowshik, *Biotechnol. Prog.*, 2011, **27**, 1464–1469.
- 73 F. G. Ortega, M. A. Fernández-Baldo, J. G. Fernández, M. J. Serrano, M. I. Sanz, J. J. Díaz-Mochón, J. A. Lorente and J. Raba, *Int. J. Nanomed.*, 2015, **10**, 2021.
- 74 H. Korbekandi, S. Mohseni, R. Mardani Jouneghani, M. Pourhossein and S. Irvani, *Artif. Cells, Nanomed., Biotechnol.*, 2016, **44**, 235–239.
- 75 X. Zhang, Y. Qu, W. Shen, J. Wang, H. Li, Z. Zhang, S. Li and J. Zhou, *Colloids Surf., A*, 2016, **497**, 280–285.
- 76 J. G. Fernández, M. A. Fernández-Baldo, E. Berni, G. Camí, N. Durán, J. Raba and M. I. Sanz, *Process Biochem.*, 2016, **51**, 1306–1313.
- 77 Z. Yang, Z. Li, X. Lu, F. He, X. Zhu, Y. Ma, R. He, F. Gao, W. Ni and Y. Yi, *Nano-Micro Lett.*, 2017, **9**, 5.
- 78 J. J. A. Bonilla, D. J. P. Guerrero, R. G. T. Sáez, K. Ishida, B. B. Fonseca, S. Rozental and C. C. O. López, *J. Nanosci. Nanotechnol.*, 2017, **17**, 1729–1739.
- 79 A. B. Moghaddam, M. Moniri, S. Azizi, R. A. Rahim, A. B. Ariff, W. Z. Saad, F. Namvar, M. Navaderi and R. Mohamad, *Molecules*, 2017, **22**, 872.
- 80 M. R. Salvadori, R. A. Ando, C. A. O. Nascimento and B. Corrêa, *J. Environ. Sci. Health, Part A: Toxic/Hazard. Subst. Environ. Eng.*, 2017, **52**, 1112–1120.
- 81 A. Rónavári, N. Igaz, M. K. Gopisetty, B. Szerencsés, D. Kovács, C. Papp, C. Vágölygyi, I. M. Boros, Z. Kónya and M. Kiricsi, *Int. J. Nanomed.*, 2018, **13**, 695.
- 82 Y. Qu, S. You, X. Zhang, X. Pei, W. Shen, Z. Li, S. Li and Z. Zhang, *Bioprocess Biosyst. Eng.*, 2018, **41**, 359–367.
- 83 F. A. Cunha, M. da CSO Cunha, S. M. da Frota, E. J. Mallmann, T. M. Freire, L. S. Costa, A. J. Paula, E. A. Menezes and P. B. Fechine, *World J. Microbiol. Biotechnol.*, 2018, **34**, 127.
- 84 M. Jalal, M. Ansari, M. Alzohairy, S. Ali, H. Khan, A. Almatroudi and K. Raees, *Nanomaterials*, 2018, **8**, 586.
- 85 V. da Silva Ferreira, M. E. ConzFerreira, L. M. T. Lima, S. Frases, W. de Souza and C. Sant'Anna, *Enzyme Microb. Technol.*, 2017, **97**, 114–121.
- 86 F. Arsiya, M. H. Sayadi and S. Sobhani, *Mater. Lett.*, 2017, **186**, 113–115.



- 87 S. Momeni and I. Nabipour, *Appl. Biochem. Biotechnol.*, 2015, **176**, 1937–1949.
- 88 T. S. Dhas, V. G. Kumar, V. Karthick, K. J. Angel and K. Govindaraju, *Spectrochim. Acta, Part A*, 2014, **120**, 416–420.
- 89 T. N. J. I. Edison, R. Atchudan, C. Kamal and Y. R. Lee, *Bioprocess Biosyst. Eng.*, 2016, **39**, 1401–1408.
- 90 M. Ramakrishna, D. R. Babu, R. M. Gengan, S. Chandra and G. N. Rao, *J. Nanostruct. Chem.*, 2016, **6**, 1–13.
- 91 S. Rajeshkumar, *Res. J. Biotechnol.*, 2018, **13**, 15–19.
- 92 Z. Sanaeimehr, I. Javadi and F. Namvar, *Cancer Nanotechnol.*, 2018, **9**, 3.
- 93 D. Fawcett, J. J. Verduin, M. Shah, S. B. Sharma and G. E. J. Poinern, *J. Nanosci.*, 2017, **2017**, 1–15.
- 94 V. Venkatpurwar and V. Pokharkar, *Mater. Lett.*, 2011, **65**, 999–1002.
- 95 F. A. A. Rajathi, C. Parthiban, V. G. Kumar and P. Anantharaman, *Spectrochim. Acta, Part A*, 2012, **99**, 166–173.
- 96 S. Senapati, A. Syed, S. Moez, A. Kumar and A. Ahmad, *Mater. Lett.*, 2012, **79**, 116–118.
- 97 R. R. R. Kannan, R. Arumugam, D. Ramya, K. Manivannan and P. Anantharaman, *Appl. Nanosci.*, 2013, **3**, 229–233.
- 98 Z. Salari, F. Danafar, S. Dabaghi and S. A. Ataei, *J. Saudi Chem. Soc.*, 2016, **20**, 459–464.
- 99 J. Jena, N. Pradhan, R. R. Nayak, B. P. Dash, L. B. Sukla, P. K. Panda and B. K. Mishra, *J. Microbiol. Biotechnol.*, 2014, **24**, 522–533.
- 100 J. Annamalai and T. Nallamuthu, *Appl. Nanosci.*, 2015, **5**, 603–607.
- 101 J. Venkatesan, P. Manivasagan, S.-K. Kim, A. V. Kirthi, S. Marimuthu and A. A. Rahuman, *Bioprocess Biosyst. Eng.*, 2014, **37**, 1591–1597.
- 102 T. Kathiraven, A. Sundaramanickam, N. Shanmugam and T. Balasubramanian, *Appl. Nanosci.*, 2015, **5**, 499–504.
- 103 K. Murugan, C. M. Samidoss, C. Panneerselvam, A. Higuchi, M. Roni, U. Suresh, B. Chandramohan, J. Subramaniam, P. Madhiyazhagan and D. Dinesh, *Parasitol. Res.*, 2015, **114**, 4087–4097.
- 104 S. N. Sinha, D. Paul, N. Halder, D. Sengupta and S. K. Patra, *Appl. Nanosci.*, 2015, **5**, 703–709.
- 105 N. González-Ballesteros, S. Prado-López, J. Rodríguez-Gonzalez, M. Lastra and M. Rodríguez-Argüelles, *Colloids Surf., B*, 2017, **153**, 190–198.
- 106 N. Abdel-Raouf, N. M. Al-Enazi and I. B. Ibraheem, *Arabian J. Chem.*, 2017, **10**, S3029–S3039.
- 107 D.-Y. Kim, R. G. Saratale, S. Shinde, A. Syed, F. Ameen and G. Ghodake, *J. Cleaner Prod.*, 2018, **172**, 2910–2918.
- 108 A. Pugazhendhi, D. Prabakar, J. M. Jacob, I. Karuppusamy and R. G. Saratale, *Microb. Pathog.*, 2018, **114**, 41–45.
- 109 M. Kobayashi, S. Tomita, K. Sawada, K. Shiba, H. Yanagi, I. Yamashita and Y. Uraoka, *Opt. Express*, 2012, **20**, 24856–24863.
- 110 Q. Zeng, H. Wen, Q. Wen, X. Chen, Y. Wang, W. Xuan, J. Liang and S. Wan, *Biomaterials*, 2013, **34**, 4632–4642.
- 111 C. Mao, C. E. Flynn, A. Hayhurst, R. Sweeney, J. Qi, G. Georgiou, B. Iverson and A. M. Belcher, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 6946–6951.
- 112 A. J. Love, M. E. Taliani, S. N. Chapman and J. Shaw, *US Pat.*, No. 9,688,964, U.S. Patent and Trademark Office, Washington, DC, 2017.
- 113 J. Cao, R. H. Guenther, T. L. Sit, C. H. Opperman, S. A. Lommel and J. A. Willoughby, *Small*, 2014, **10**, 5126–5136.
- 114 D. H. Le, K. L. Lee, S. Shukla, U. Commandeur and N. F. Steinmetz, *Nanoscale*, 2017, **9**, 2348–2357.
- 115 F. Yang, Y. Li, T. Liu, K. Xu, L. Zhang, C. Xu and J. Gao, *Chem. Eng. J.*, 2013, **226**, 52–58.
- 116 P.-Y. Chen, X. Dang, M. T. Klug, N.-M. D. Courchesne, J. Qi, M. N. Hyder, A. M. Belcher and P. T. Hammond, *Chem. Mater.*, 2015, **27**, 1531–1540.
- 117 N. Esfandiari, M. K. Arzanani, M. Soleimani, M. Kohi-Habibi and W. E. Svendsen, *Tumor Biol.*, 2016, **37**, 1229–1236.
- 118 C. C. Chen, M. Stark, M. Baikoghli and R. H. Cheng, *J. Visualized Exp.*, 2018, e57020.
- 119 A. H. Tanzil, S. T. Sultana, S. R. Saunders, L. Shi, E. Marsili and H. Beyenal, *Enzyme Microb. Technol.*, 2016, **95**, 4–12.
- 120 D. L. Cologgi, S. Lampa-Pastirk, A. M. Speers, S. D. Kelly and G. Reguera, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, 201108616.
- 121 G. Reguera, *Biochem. Soc. Trans.*, 2012, **40**, 1227–1232.
- 122 S. I. Vasylevskyi, S. Kracht, P. Corcosa, K. M. Fromm, B. Giese and M. Füeg, *Angew. Chem., Int. Ed.*, 2017, **56**, 5926–5930.
- 123 K. D. Bewley, K. E. Ellis, M. A. Firer-Sherwood and S. J. Elliott, *Biochim. Biophys. Acta, Bioenerg.*, 2013, **1827**, 938–948.
- 124 L. Shi, K. M. Rosso, T. A. Clarke, D. J. Richardson, J. M. Zachara and J. K. Fredrickson, *Front. Microbiol.*, 2012, **3**, 50.
- 125 M. L. Rodrigues, T. F. Oliveira, I. A. Pereira and M. Archer, *EMBO J.*, 2006, **25**, 5951–5960.
- 126 M. L. Rodrigues, K. A. Scott, M. S. Sansom, I. A. Pereira and M. Archer, *J. Mol. Biol.*, 2008, **381**, 341–350.
- 127 R. S. Hartshorne, C. L. Reardon, D. Ross, J. Nuester, T. A. Clarke, A. J. Gates, P. C. Mills, J. K. Fredrickson, J. M. Zachara, L. Shi, A. S. Beliaev, M. J. Marshall, M. Tien, S. Brantley, J. N. Butt and D. J. Richardson, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 22169–22174.
- 128 T. A. Clarke, T. Holley, R. S. Hartshorne, J. K. Fredrickson, J. M. Zachara, L. Shi and D. J. Richardson, *Biochem. Soc. Trans.*, 2008, **36**, 1005–1010.
- 129 T. A. Clarke, M. J. Edwards, A. J. Gates, A. Hall, G. F. White, J. Bradley, C. L. Reardon, L. Shi, A. S. Beliaev, M. J. Marshall, Z. Wang, N. J. Watmough, J. K. Fredrickson, J. M. Zachara, J. N. Butt and D. J. Richardson, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 9384–9389.
- 130 D. Coursolle and J. A. Gralnick, *Mol. Microbiol.*, 2010, **77**, 995–1008.
- 131 C. K. Ng, K. Sivakumar, X. Liu, M. Madhaiyan, L. Ji, L. Yang, C. Tang, H. Song, S. Kjelleberg and B. Cao, *Biotechnol. Bioeng.*, 2013, **110**, 1831–1837.



- 132 Y. Liu, Z. Wang, J. Liu, C. Levar, M. J. Edwards, J. T. Babauta, D. W. Kennedy, Z. Shi, H. Beyenal and D. R. Bond, *Environ. Microbiol. Rep.*, 2014, **6**, 776–785.
- 133 Y. Liu, J. K. Fredrickson, J. M. Zachara and L. Shi, *Front. Microbiol.*, 2015, **6**, 1075.
- 134 F. Kang, P. J. Alvarez and D. Zhu, *Environ. Sci. Technol.*, 2013, **48**, 316–322.
- 135 A. R. Choudhury, A. Malhotra, P. Bhattacharjee and G. Prasad, *Carbohydr. Polym.*, 2014, **106**, 154–159.
- 136 F. Freitas, V. D. Alves and M. A. M. Reis, *Trends Biotechnol.*, 2011, **29**, 388–398.
- 137 I. W. Sutherland, *Trends Microbiol.*, 2001, **9**, 222–227.
- 138 T. Gutierrez, G. Morris and D. H. Green, *Biotechnol. Bioeng.*, 2009, **103**, 207–216.
- 139 D. C. O. Thornton, E. M. Fejes, S. F. DiMarco and K. M. Clancy, *Limnol. Oceanogr.: Methods*, 2007, **5**, 73–87.
- 140 G. Sathiyarayanan, K. Dineshkumar and Y.-H. Yang, *Crit. Rev. Microbiol.*, 2017, **43**, 731–752.
- 141 A. Banerjee, U. Halder and R. Bandopadhyay, *J. Cluster Sci.*, 2017, **28**, 1803–1813.
- 142 H. E. Emam and H. B. Ahmed, *Carbohydr. Polym.*, 2016, **135**, 300–307.
- 143 S. Pandey, G. K. Goswami and K. K. Nanda, *Int. J. Biol. Macromol.*, 2012, **51**, 583–589.
- 144 Y. N. Mata, E. Torres, M. L. Blázquez, A. Ballester, F. González and J. A. Muñoz, *J. Hazard. Mater.*, 2009, **166**, 612–618.
- 145 W. Xu, W. Jin, L. Lin, C. Zhang, Z. Li, Y. Li, R. Song and B. Li, *Carbohydr. Polym.*, 2014, **101**, 961–967.
- 146 D. Pooja, S. Panyaram, H. Kulhari, S. S. Rachamalla and R. Sistla, *Carbohydr. Polym.*, 2014, **110**, 1–9.
- 147 S. Davidović, V. Lazić, I. Vukoje, J. Papan, S. P. Anhrenkiel, S. Dimitrijević and J. M. Nedeljković, *Colloids Surf., B*, 2017, **160**, 184–191.
- 148 D. Medhat, J. Hussein, M. E. El-Naggar, M. F. Attia, M. Anwar, Y. A. Latif, H. F. Booles, S. Morsy, A. R. Farrag, W. K. Khalil and Z. El-Khayat, *Biomed. Pharmacother.*, 2017, **91**, 1006–1016.
- 149 Z. Shaterabadi, G. Nabyouni and M. Soleymani, *Mater. Sci. Eng., C*, 2017, **75**, 947–956.
- 150 J. K. Yan, P. F. Cai, X. Q. Cao, H. L. Ma, Q. Zhang, N. Z. Hu and Y. Z. Zhao, *Carbohydr. Polym.*, 2013, **97**, 391–397.
- 151 J. K. Yan, J. L. Liu, Y. J. Sun, S. Tang, Z. Y. Mo and Y. S. Liu, *Carbohydr. Polym.*, 2015, **117**, 771–777.
- 152 J.-W. Moon, I. N. Ivanov, P. C. Joshi, B. L. Armstrong, W. Wang, H. Jung, A. J. Rondinone, G. E. Jellison Jr, H. M. Meyer III and G. G. Jang, *Acta Biomater.*, 2014, **10**, 4474–4483.
- 153 A. Ramos-Ruiz, J. Sesma-Martin, R. Sierra-Alvarez and J. A. Field, *Water Res.*, 2017, **108**, 189–196.
- 154 J.-W. Moon, C. J. Rawn, A. J. Rondinone, L. J. Love, Y. Roh, S. M. Everett, R. J. Lauf and T. J. Phelps, *J. Ind. Microbiol. Biotechnol.*, 2010, **37**, 1023–1031.
- 155 J.-W. Moon, I. N. Ivanov, C. E. Duty, L. J. Love, A. J. Rondinone, W. Wang, Y.-L. Li, A. S. Madden, J. J. Mosher and M. Z. Hu, *J. Ind. Microbiol. Biotechnol.*, 2013, **40**, 1263–1271.
- 156 J.-W. Moon, T. J. Phelps, C. L. Fitzgerald Jr, R. F. Lind, J. G. Elkins, G. G. Jang, P. C. Joshi, M. Kidder, B. L. Armstrong and T. R. Watkins, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 7921–7931.
- 157 K. Ikuma, A. W. Decho and B. L. T. Lau, *Front. Microbiol.*, 2015, **6**, 1–6.
- 158 S. Kalathil, J. Lee and M. H. Cho, *Green Chem.*, 2011, **13**, 1482–1485.
- 159 M. M. Khan, S. Kalathil, T. H. Han, J. Lee and M. H. J. Cho, *J. Nanosci. Nanotechnol.*, 2013, **13**, 6079–6085.
- 160 G. M. Teitzel and M. R. Parsek, *Appl. Environ. Microbiol.*, 2003, **69**, 2313–2320.
- 161 M. M. Khan, S. A. Ansari, J. H. Lee, M. O. Ansari, J. Lee and M. H. Cho, *J. Colloid Interface Sci.*, 2014, **431**, 255–263.
- 162 D. Mandal, M. E. Bolander, D. Mukhopadhyay, G. Sarkar and P. Mukherjee, *Appl. Microbiol. Biotechnol.*, 2006, **69**, 485–492.
- 163 A. Roy, O. Bulut, S. Some, A. K. Mandal and M. D. Yilmaz, *RSC Adv.*, 2019, **9**, 2673–2702.
- 164 L. Jayasree, P. Janakiram and R. Madhavi, *J. World Aquacult. Soc.*, 2006, **37**, 523–532.
- 165 E. Oberdorster, *Environ. Health Perspect.*, 2004, **112**, 1058–1062.
- 166 M. Rai, A. Yadav and A. Gade, *Biotechnol. Adv.*, 2009, **27**, 76–83.
- 167 C. Carlson, S. M. Hussain, A. M. Schrand, L. K. Braydich-Stolle, K. L. Hess, R. L. Jones and J. J. Schlager, *J. Phys. Chem. B*, 2008, **112**, 13608–13619.
- 168 W. Liu, Y. Wu, C. Wang, H. C. Li, T. Wang, C. Y. Liao, L. Cui, Q. F. Zhou, B. Yan and G. B. Jiang, *Nanotoxicology*, 2010, **4**, 319–330.
- 169 J. J. Lin, W. C. Lin, R. X. Dong and S. Hsu, *Nanotechnology*, 2012, **23**, 065102.
- 170 I. K. Sen, A. K. Mandal, S. Chakraborti, B. Dey, R. Chakraborty and S. S. Islam, *Int. J. Biol. Macromol.*, 2013, **62**, 439–449.
- 171 D. K. Manna, A. K. Mandal, I. K. Sen, P. K. Maji, S. Chakraborti, R. Chakraborty and S. S. Islam, *Int. J. Biol. Macromol.*, 2015, **80**, 455–459.
- 172 A. Abbaszadegan, Y. Ghahramani, A. Gholami, B. Hemmateenejad, S. Dorostkar, M. Nabavizadeh and H. Sharghi, *J. Nanomater.*, 2015, **2015**, 1–8.
- 173 B. Ramalingam, T. Parandhaman and S. K. Das, *ACS Appl. Mater. Interfaces*, 2016, **8**, 4963–4976.
- 174 A. Ahmad, Y. Wei, F. Syed, K. Tahir, A. U. Rehman, A. Khan, S. Ullah and Q. Yuan, *Microb. Pathog.*, 2017, **102**, 133–142.
- 175 E. Z. Goma, *J. Gen. Appl. Microbiol.*, 2017, **63**, 36–43.
- 176 A. Ravichandran, P. Subramanian, V. Manoharan, T. Muthu, R. Periyannan, M. Thangapandi, K. Ponnuchamy, B. Pandi and P. N. Marimuthu, *J. Photochem. Photobiol., B*, 2018, **185**, 117–125.
- 177 Y. G. Yuan, Q. L. Peng and S. Gurunathan, *Int. J. Mol. Sci.*, 2017, **18**, 569.
- 178 M. A. Ansari and M. A. Alzohairy, *J. Evidence-Based Complementary Altern. Med.*, 2018, **2018**, 1–9.



- 179 S. Ninganagouda, V. Rathod, D. Singh, J. Hiremath, A. K. Singh, J. Mathew and M. ul-Haq, *BioMed Res. Int.*, 2014, **2014**, 753419.
- 180 B. Buszewski, V. Railean-Plugaru, P. Pomastowski, K. Rafińska, M. Szultka-Mlynska, P. Golinska, M. Wypij, D. Laskowski and H. Dahm, *J. Microbiol., Immunol. Infect.*, 2018, **51**, 45–54.
- 181 B. Chopade, S. Ghosh, M. Patil, R. Ahire, S. Kitture, K. Jabgunde, S. S. Kale, J. Pardesi, D. D. Cameotra, A. Bellare and B. A. Dhavale, *Int. J. Nanomed.*, 2012, **7**, 483.
- 182 H. S. Toh, C. Batchelor-McAuley, K. Tschulik and R. G. Compton, *Sci. China: Chem.*, 2014, **57**, 1199–1210.
- 183 C. N. Lok, C. M. Ho, R. Chen, Q. Y. He, W. Y. Yu, H. Sun, P. K. H. Tam, J. F. Chiu and C. M. Che, *J. Proteome Res.*, 2006, **5**, 916–924.
- 184 J. S. McQuillan and A. M. Shaw, *Nanotoxicology*, 2014, **8**, 177–184.
- 185 S. K. Gogoi, P. Gopinath, A. Paul, A. Ramesh, S. S. Ghosh and A. Chattopadhyay, *Langmuir*, 2006, **22**, 9322–9328.
- 186 Y. H. Hsueh, K. S. Lin, W. J. Ke, C. T. Hsieh, C. L. Chiang, D. Y. Tzou and S. T. Liu, *PLoS One*, 2015, **10**, e0144306.
- 187 Q. Feng, J. Wu and G. Chen, *J. Biomed. Mater. Res.*, 2000, **52**, 662–668.
- 188 S. J. Soenen, P. Rivera-Gil, J. M. Montenegro, W. J. Parak, S. C. De Smedt and K. Braeckmans, *Nano Today*, 2011, **6**, 446–465.
- 189 B. Das, S. K. Dash, D. Mandal, T. Ghosh, S. Chattopadhyay, S. Tripathy, S. Das, S. K. Dey, D. Das and S. Roy, *Arabian J. Chem.*, 2017, **10**, 862–876.
- 190 S. Belluco, C. Losasso, I. Patuzzi, L. Rigo, D. Conficoni, F. Gallochio, V. Cibir, P. Catellani, S. Segato and A. Ricci, *Front. Microbiol.*, 2016, **7**, 307.
- 191 K. Soo-Hwan, H. Seon Lee, D. Seon Ryu, S. Jae Choi and D. Seok Lee, *Korean J. Microbiol. Biotechnol.*, 2011, **39**, 77–85.

